


WHO GUIDELINES FOR THE

Treatment of *Chlamydia trachomatis*



WHO GUIDELINES FOR THE

Treatment of *Chlamydia trachomatis*



World Health
Organization

WHO Library Cataloguing-in-Publication Data

WHO guidelines for the treatment of Chlamydia trachomatis.

Contents: Web annex D: Evidence profiles and evidence-to-decision framework -- Web annex E: Systematic reviews -- Web annex F: Summary of conflicts of interest

1.Chlamydia trachomatis. 2.Chlamydia Infections - drug therapy.
3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization.

ISBN 978 92 4 154971 4 (NLM classification: WC 600)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

Acknowledgements	iii
Abbreviations and acronyms	iv
Executive summary	1
Overview of the guidelines for the prevention, treatment and management of STIs	6
STI epidemiology and burden	6
Why new guidelines for the prevention, treatment and management of STIs?	6
Approach to the revision of STI guidelines	8
References	9
WHO guidelines for the treatment of <i>Chlamydia trachomatis</i>	10
1. Introduction	10
1.1 Epidemiology, burden and clinical considerations	10
Clinical presentation	10
Laboratory diagnosis	11
1.2 Rationale for new recommendations	11
1.3 Objectives	11
1.4 Target audience	11
1.5 Structure of the guidelines	11
2. Methods	12
2.1 Guideline Development Group (GDG)	12
2.2 Questions and outcomes	12
2.3 Reviews of the evidence	12
2.4 Making recommendations	13
2.5 Management of conflicts of interest	14
3. Dissemination, updating and implementation of the guidelines	15
3.1 Dissemination	15
3.2 Updating the STI guidelines and user feedback	15
3.3 Implementation of the WHO guidelines for the treatment of <i>C. trachomatis</i>	15
Adaptation, implementation and monitoring	15
Identifying and procuring STI drugs	16
4. Recommendations for treatment of chlamydial infections	17
4.1 Uncomplicated genital chlamydia	17
Recommendation 1	17
4.2 Anorectal chlamydial infection	18
Recommendation 2	18
4.3 Chlamydial infection in pregnant women	19
Recommendation 3a	19
Recommendation 3b	19
Recommendation 3c	19
4.4 Lymphogranuloma venereum (LGV)	20
Recommendation 4	20

CONTENTS (CONTINUED)

4.5 Ophthalmia neonatorum	20
Recommendation 5	20
Recommendation 6	21
Recommendation 7	21
References	22
Annex A: STI guideline development teams	23
Annex B: Detailed methods for guideline development	32
Questions and outcomes	32
Review of the evidence	35
Applying the GRADE approach to making the recommendations	38
Annex C: Lists of references for reviewed evidence	39
Recommendation 1	39
Recommendation 2	40
Recommendation 3a, 3b, 3c	41
Recommendation 4	42
Recommendation 5	43
Recommendations 6 and 7	43

Web annexes available at:

www.who.int/reproductivehealth/publications/rtis/chlamydia-treatment-guidelines/en/

Web annex D: Evidence profiles and evidence-to-decision frameworks

Web annex E: Systematic reviews for chlamydia guidelines

Web annex F: Summary of conflicts of interest

ACKNOWLEDGEMENTS

The Department of Reproductive Health and Research at the World Health Organization (WHO) would like to thank the members of the STI Guideline Development Group for their consistent availability and commitment to making these guidelines possible. The Department is also grateful to the STI External Review Group for peer reviewing these guidelines, and appreciates the contribution of the WHO Steering Committee. The names of the members of each group are listed below, with full details provided in Annex A.

Special thanks to Dr Nancy Santesso, the guideline methodologist who also led the systematic review process, for her hard work and firm commitment of the guideline development process. We also thank the members of the Systematic Review Team from McMaster University.

We appreciate the overall support of the WHO Guideline Review Committee Secretariat during the guideline development process, with grateful thanks to Dr Susan Norris.

We thank Theresa Ryle for the administrative support and 400 Communications for assistance with the guideline design and layout. This guideline document was edited by Ms Jane Patten, of Green Ink, United Kingdom.

Dr Teodora Wi led the guideline development process and Dr Nathalie Broutet co-led the process under the supervision of Dr James Kiarie and leadership of Dr Ian Askew. Lee Sharkey provided support during the guideline development process.

FUNDING

The preparation and printing of the guidelines were funded exclusively by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). No external source of funding was solicited or utilized.

CONTRIBUTORS TO WHO GUIDELINES FOR THE TREATMENT OF *CHLAMYDIA TRACHOMATIS*

STI Guideline Development Group (GDG):

Chairpersons: Judith Wasserheit, Holger Schünemann and Patricia Garcia

Members: Yaw (Sax) Adu-Sarkodie, Andrew Amato, Gail Bolan, John Changalucha, Xiang-Sheng Chen, Harrel Chesson, Craig Cohen, Francisco Garcia, Suzanne Garland, Sarah Hawkes, Mary Higgins, King Holmes, Jeffrey Klausner, David Lewis, Nicola Low, David Mabey, Angelica Espinosa Miranda, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Keith Radcliffe, Ulugbek Sabirov, Judith Stephenson, Richard Steen, Magnus Unemo, Bea Vuylsteke, Anna Wald, Thomas Wong and Kimberly A. Workowski

STI GDG working group for chlamydia:

Andrew Amato, Harrell Chesson, Craig Cohen, Patricia Garcia, Nicola Low, David Mabey, Angelica Miranda, Francis Ndowa, Keith Radcliffe, Judith Stephenson, Magnus Unemo, Bea Vuylsteke and Judith Wasserheit

STI External Review Group: Laith Abu-Raddad, Adele Benaken-Schwartz, Mircea Betiu, Anupong Chitwarakorn, Anjana Das, Carolyn Deal, Margaret Gale-Rowe, William M. Geisler, Amina El Kettani, Mizan Kiros, Ahmed Latif, Philippe Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, Khantanouvieng Sayabounthavong and Aman Kumar Singh

WHO Steering Committee:

WHO regional offices: Massimo Ghidinelli, Hamida Khattabi, Lali Khotenashvili, Ornella Lincetto Ying-Ru Lo, Frank Lule and Razia Pendse

WHO headquarters: Moazzam Ali, Avni Amin, Rachel Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, Mario Festin, Mary Lyn Gaffield, Antonio Gerbase, Sami Gottlieb, Silvio Paolo Mariotti, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, Igor Toskin and Marco Vitoria

WHO STI Secretariat: Ian Askew, Teodora Elvira Wi (lead, development of the guidelines), Nathalie Broutet (co-lead, development of the guidelines), James Kiarie and Lee Sharkey

Systematic Review Team: Nancy Santesso (lead), Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, Kristie Poole, Nicole Schwab, Matthew Ventresca, Yuan Zhang and Andrew Zikic (members)

Methodologist: Nancy Santesso.

ABBREVIATIONS AND ACRONYMS

AIDS	acquired immune deficiency syndrome
AMR	antimicrobial resistance
DALY	disability-adjusted life year
DFA	direct fluorescent antibody
DOI	declaration of interests
ELISA	enzyme-linked immunosorbent assays
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GUD	genital ulcer disease
HIV	human immunodeficiency virus
HPV	human papillomavirus
HRP	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction
HSV-2	herpes simplex virus type 2
LGV	lymphogranuloma venereum
MSH	Management Sciences for Health
MSM	men who have sex with men
NAATs	nucleic acid amplification tests (NAATs)
PICO	population, intervention, comparator, outcome
POCT	point-of-care test
STI	sexually transmitted infection
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
WHO	World Health Organization

WHO GUIDELINES FOR THE TREATMENT OF *CHLAMYDIA TRACHOMATIS*

EXECUTIVE SUMMARY

Sexually transmitted infections (STIs) are a major public health problem worldwide, affecting quality of life and causing serious morbidity and mortality. STIs have a direct impact on reproductive and child health through infertility, cancers and pregnancy complications, and they have an indirect impact through their role in facilitating sexual transmission of human immunodeficiency virus (HIV) and thus they also have an impact on national and individual economies. More than a million STIs are acquired every day. In 2012, an estimated 357 million new cases of curable STIs (gonorrhoea, chlamydia, syphilis and trichomoniasis) occurred among 15–49 year-olds worldwide, including 131 million cases of chlamydial infection.

Chlamydial infection, caused by *Chlamydia trachomatis*, is the most common bacterial STI and results in substantial morbidity and economic cost worldwide. Occurring most commonly among young sexually active adults, *C. trachomatis* causes cervicitis in women and urethritis in men, as well as extra-genital infections, including rectal and oropharyngeal infections. Asymptomatic infections are common in both men and women. Untreated chlamydial infection may cause severe complications in the upper reproductive tract, primarily in young women, including ectopic pregnancy, salpingitis and infertility. Lymphogranuloma venereum (LGV), caused by a more invasive serovar of *C. trachomatis*, is increasingly prevalent among men who have sex with men (MSM) in some settings. Maternal infection is associated with serious adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection and pneumonia. *C. trachomatis* can be diagnosed by culture, direct immunofluorescence assays (DFAs) and enzyme-linked immunosorbent assays (ELISAs), but nucleic acid amplification tests (NAATs) are preferred due to their superior performance characteristics.

RATIONALE FOR THE GUIDELINES

Since the publication of the World Health Organization (WHO) Guidelines for the management of sexually transmitted infections in 2003, changes in the epidemiology of STIs and advancements in prevention, diagnosis and treatment necessitate changes in STI management. These guidelines provide updated treatment recommendations for common infections caused by *C. trachomatis* based on the most recent evidence; they form one of several modules of guidelines for specific STIs. Other modules will focus on treatments for *Neisseria gonorrhoeae* (gonorrhoea), herpes simplex virus type 2 (HSV-2; genital herpes) and *Treponema pallidum* (syphilis). In addition, future work will provide guidance for syphilis screening and treatment of pregnant women, STI syndromic approach, clinical management, STI prevention, and treatments of other STIs. It is strongly recommended that countries take updated global guidance into account as they establish standardized national protocols, adapting this guidance to the local epidemiological situation and antimicrobial susceptibility data.

OBJECTIVES

The objectives of these guidelines are:

- to provide evidence-based guidance on treatment of infection with *C. trachomatis*; and
- to support countries to update their national guidelines for treatment of chlamydial infection.

METHODS

These guidelines were developed following the methods outlined in the 2014 WHO handbook for guideline development. The Guideline Development Group (GDG) included international STI experts, clinicians, researchers and programme managers. The GDG prioritized questions and outcomes related to treatment of chlamydial infections to include in this update, and a methodologist and a team of systematic reviewers from McMaster University, the WHO Collaborating Centre for Evidence-Informed Policy, independently conducted systematic reviews of the effectiveness of different treatments for chlamydial infections. The evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and presented to the GDG. Conflicts of interest were managed according to WHO guidelines and declared before the recommendations were discussed and finalized. Research implications were also developed by the GDG.

RECOMMENDATIONS

The current guidelines provide nine treatment recommendations for genital infections and LGV caused by *C. trachomatis*. The recommendations summarized in Table 1 apply to adults, adolescents (10–19 years of age), people living with HIV and key populations, including sex workers, MSM and transgender persons. Specific recommendations have also been developed for genital chlamydial infection in pregnant women and for prophylaxis and treatment of ophthalmia neonatorum caused by *C. trachomatis*.

Table 1. Summary of recommendations for treatment of chlamydial infections

Recommendations	Strength of recommendation and quality of evidence
Uncomplicated genital chlamydia	
<p>Recommendation 1</p> <p>The WHO STI guideline suggests treatment with one of the following options:</p> <ul style="list-style-type: none"> • azithromycin 1 g orally as a single dose • doxycycline 100 mg orally twice a day for 7 days <p>or one of these alternatives:</p> <ul style="list-style-type: none"> • tetracycline 500 mg orally four times a day for 7 days • erythromycin 500 mg orally four times a day for 7 days • ofloxacin 200–400 mg orally twice a day for 7 days. <p><i>Remarks:</i> While good practice based on evidence of large net benefit dictates that patients should be treated for chlamydial infection, the choice of treatment may depend on the convenience of dosage, the cost and quality of the medicines in different settings, and equity considerations. When high value is placed on reducing costs, doxycycline in a standard dose may be the best choice; when high value is placed on convenience, azithromycin in a single dose may be the best choice. A delayed-release doxycycline formulation may be an alternative to twice daily dosing of doxycycline, but the high cost of the delayed-release formulation may prohibit its use. Note that doxycycline, tetracycline and ofloxacin are contraindicated in pregnant women (see recommendations 3a–3c).</p>	<p><i>Conditional recommendation, moderate quality evidence</i></p>
Anorectal chlamydial infection	
<p>Recommendation 2</p> <p>The WHO STI guideline suggests treatment with doxycycline 100 mg orally twice a day for 7 days over azithromycin 1 g orally as a single dose.</p> <p><i>Remarks:</i> This recommendation applies to people with known anorectal infection and to people with suspected anorectal infections with genital co-infection. Clinicians should ask men, women and key populations (e.g. men who have sex with men, transgender persons and female sex workers) about anal sex and treat accordingly. Doxycycline should not be used in pregnant women because of adverse effects (see recommendations 3a–3c).</p>	<p><i>Conditional recommendation, low quality evidence</i></p>

Genital chlamydial infection in pregnant women	
<p>Recommendation 3a The WHO STI guideline recommends treatment with azithromycin over erythromycin.</p> <p>Recommendation 3b The WHO STI guideline suggests treatment with azithromycin over amoxicillin.</p> <p>Recommendation 3c The WHO STI guideline suggests treatment with amoxicillin over erythromycin.</p> <p>Dosages:</p> <ul style="list-style-type: none"> • azithromycin 1 g orally as a single dose • amoxicillin 500 mg orally three times a day for 7 days • erythromycin 500 mg orally four times a day for 7 days. <p><i>Remarks:</i> Azithromycin is the first choice of treatment but may not be available in some settings. Azithromycin is less expensive than erythromycin and since it is provided as a single dose, may result in better adherence and therefore better outcomes.</p>	<p><i>Strong recommendation, moderate quality evidence</i></p> <p><i>Conditional recommendation, low quality evidence</i></p> <p><i>Conditional recommendation, low quality evidence</i></p>
Lymphogranuloma venereum (LGV)	
<p>Recommendation 4 The WHO STI guideline suggests treatment with doxycycline 100 mg orally twice daily for 21 days over azithromycin 1 g orally, weekly for 3 weeks.</p> <p><i>Remarks:</i> Good practice dictates effective treatment of LGV, in particular for men who have sex with men and for people living with HIV. When doxycycline is contraindicated, azithromycin should be provided. When neither treatment is available, erythromycin 500 mg orally four times a day for 21 days is an alternative. Doxycycline should not be used in pregnant women because of adverse effects (see recommendations 3a–3c).</p>	<p><i>Conditional recommendation, very low quality evidence</i></p>
Ophthalmia neonatorum	
<p>Recommendation 5 In neonates with chlamydial conjunctivitis, the WHO STI guideline recommends treatment with azithromycin 20 mg/kg/day orally, one dose daily for 3 days, over erythromycin 50 mg/kg/day orally, in four divided doses daily for 14 days.</p> <p><i>Remarks:</i> This is a strong recommendation given the potential for the risk of pyloric stenosis with the use of erythromycin in neonates. In some settings, azithromycin suspension is not available and therefore erythromycin may be used. Side-effects should be monitored with the use of either medication.</p>	<p><i>Strong recommendation, very low quality evidence</i></p>

OVERVIEW OF THE GUIDELINES FOR THE PREVENTION, TREATMENT AND MANAGEMENT OF STIs

STI EPIDEMIOLOGY AND BURDEN

Sexually transmitted infections (STIs) are a major public health problem worldwide, affecting quality of life and causing serious morbidity and mortality. STIs have a direct impact on reproductive and child health through infertility, cancers and pregnancy complications, and they have an indirect impact through their role in facilitating sexual transmission of human immunodeficiency virus (HIV) and thus they also have an impact on national and individual economies. The prevention and control of STIs is an integral component of comprehensive sexual and reproductive health services that are needed to attain the related targets under Sustainable Development Goal (SDG) No. 3 (Ensure healthy lives and promote well-being for all at all ages), including: target 3.2 – to end preventable deaths of newborns and children under 5 years of age; target 3.3 – to end the epidemics of AIDS and other communicable diseases; target 3.4 – to reduce premature mortality from noncommunicable diseases and promote mental health and well-being; target 3.7 – to ensure universal access to sexual and reproductive health-care services; and target 3.8 – to achieve universal health coverage.

Worldwide, more than a million curable STIs are acquired every day. In 2012, there were an estimated 357 million new cases of curable STIs among adults aged 15–49 years worldwide: 131 million cases of chlamydia, 78 million cases of gonorrhoea, 6 million cases of syphilis and 142 million cases of trichomoniasis (1). The prevalence of some viral STIs is similarly high, with an estimated 417 million people infected with herpes simplex virus type 2 (HSV-2) (2), and approximately 291 million women harbouring human papillomavirus (HPV) at any point in time (3). The burden of STIs varies by region and gender, and is greatest in resource-poor countries.

When left undiagnosed and untreated, curable STIs can result in serious complications and sequelae, such as pelvic inflammatory disease, infertility, ectopic pregnancy, miscarriage, fetal loss and congenital infections. In 2012, an estimated 930 000 maternal syphilis infections resulted in 350 000 adverse pregnancy outcomes, including stillbirths, neonatal deaths, preterm births and infected infants (4). Curable STIs accounted for the loss of nearly 11 million disability-adjusted life years (DALYs) in 2010 (5). The psychological consequences of STIs include stigma, shame and loss of self-worth. STIs have also been associated with relationship disruption and gender-based violence (6).

Both ulcerative and non-ulcerative STIs are associated with a several-fold increased risk of transmitting or acquiring HIV (7, 8). Infections causing genital ulcers are associated with the highest HIV transmission risk; in addition to curable ulcer-causing STIs (e.g. syphilis and chancroid), highly prevalent HSV-2 infections substantially increase that risk (9). Non-ulcerative STIs, such as gonorrhoea, chlamydia and trichomoniasis, have been shown to increase HIV transmission through genital shedding of HIV (10). Treating STIs with the right medicines at the right time is necessary to reduce HIV transmission and improve sexual and reproductive health (11). Efforts should therefore be taken to strengthen STI diagnosis and treatment.

WHY NEW GUIDELINES FOR THE PREVENTION, TREATMENT AND MANAGEMENT OF STIs?

Since the publication of the World Health Organization (WHO) Guidelines for the management of sexually transmitted infections in 2003, changes in the epidemiology of STIs and advancements in prevention, diagnosis and treatment necessitate changes in STI management. Indeed, 88% of countries have updated their national STI guidelines or recommendations since 2006 (12). Updated global guidance reflecting the most recent evidence and expert opinion is therefore needed to assist countries to incorporate new developments into an effective national approach to the prevention and treatment of STIs.

There is an urgent need to update global treatment recommendations to effectively respond to the changing antimicrobial resistance (AMR) patterns of STIs, especially for *Neisseria gonorrhoeae*. Effective treatment protocols that take into account global and local resistance patterns are essential to reduce the risk of further development of AMR. High-level gonococcal resistance to quinolones, a previously recommended first-line treatment, is widespread and decreased susceptibility to the extended-spectrum (third-generation) cephalosporins, another first-line treatment for gonorrhoea, is on the rise (13). Low-level resistance to *Trichomonas vaginalis* has also been reported for nitroimidazoles, the only available treatment. Resistance to azithromycin has been reported in some strains of *Treponema pallidum* and treatment failures have been reported for tetracyclines and macrolides in the treatment of *Chlamydia trachomatis* (14, 15).

A WHO STI expert consultation recommended updating the WHO 2003 guidelines for the first- and second-line treatments for *C. trachomatis*, increasing the dosage of ceftriaxone to 250 mg for treatment of *N. gonorrhoeae* with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).

The epidemiology of STIs is changing, with viral pathogens becoming more prevalent than bacterial etiologies for some conditions; this means that updated information is required to inform locally appropriate prevention and treatment strategies. An increasing proportion of genital ulcers are now due to viral infections as previously common bacterial infections, such as chancroid, approach elimination in many countries (16, 17). As recommended during the STI expert consultation, treatment guidelines for genital ulcer disease (GUD) should be updated to include HSV-2 treatment and a longer treatment duration for HSV-2 should be explored. In addition, suppressive therapy for HSV-2 should be considered in areas with high HIV prevalence (16). The chronic, lifelong nature of viral infections also requires that renewed attention be paid to developing effective prevention strategies, including expanding accessibility to available vaccines for HPV and development of new vaccines for HSV-2.

In the 2003 WHO guidelines, a syndromic approach was recommended for the management of STIs. The approach guides the diagnosis of STIs based on identification of consistent groups of symptoms and easily recognized signs and indicates treatment for the majority of organisms that may be responsible for producing the syndrome. The syndromic management algorithms need to be updated in response to the changing situation. In addition to changes to the GUD algorithm, other syndromes need to be re-evaluated, particularly vaginal discharge. The approach to syndromes for key populations also needs to be updated. For example, addition of a syndromic management algorithm for anorectal infections in men who have sex with men (MSM) and sex workers is urgently needed since a substantial number of these infections go unrecognized and untreated in the absence of guidelines (16).

New rapid, point-of-care diagnostic tests (POCTs) are changing STI management. Rapid syphilis diagnostic tests are now widely available, making syphilis screening more widely accessible and allowing for earlier initiation of treatment for those who test positive. Efforts are under way to develop POCTs for other STIs that will augment syndromic management of symptomatic cases and increase the ability to identify asymptomatic infections (12). Updated guidelines are needed that incorporate rapid tests into syndromic management of STIs and provide algorithms for testing and screening (16).

Although recent technological advances in diagnostics, therapeutics, vaccines and barrier methods offer better opportunities for the prevention and care of STIs, access to these technologies is still limited, particularly in areas where the burden of infection is highest. For optimal effectiveness, global guidelines for the management of STIs need to include approaches for settings with limited access to modern technologies, as well as for settings in which these technologies are available.

It is strongly recommended that countries take updated global guidance into account as they establish standardized national protocols, adapting this guidance to the local epidemiological situation and antimicrobial susceptibility data. Standardization ensures that all patients receive adequate treatment at every level of health-care services, optimizes the training and supervision of health-care providers and facilitates procurement of medicines. It is recommended that national guidelines for the effective management of STIs be developed in close consultation with local STI, public health and laboratory experts.

APPROACH TO THE REVISION OF STI GUIDELINES

To ensure effective treatment for all STIs, WHO plans a phased approach to updating the STI guidelines to address a range of infections and issues. Four phases have been proposed by the WHO STI Secretariat and agreed upon by the STI Guideline Development Group (GDG) members (see Annex A for members of these groups). Table 2 summarizes the proposed phases and timeline.

Table 2: Phases for development of the STI guidelines

Phases	Topics	Timeframe
Phase 1	Treatment of specific STIs: <i>Chlamydia trachomatis</i> (chlamydia), <i>Neisseria gonorrhoeae</i> (gonorrhoea), HSV-2 (genital herpes) and <i>Treponema pallidum</i> (syphilis) Syphilis screening and treatment of pregnant women	November 2013 – April 2016
	STI syndromic approach Clinical management package	May 2016 – December 2017
Phase 2	STI prevention: condoms, behaviour change communication, biomedical interventions and vaccines	2017–2018
Phase 3	Treatment of specific STIs and reproductive tract infections (RTIs) not addressed in Phase 1: <i>Trichomonas vaginalis</i> (trichomoniasis), bacterial vaginosis, <i>Candida albicans</i> (candidiasis), <i>Hemophilus ducreyi</i> (chancroid), <i>Klebsiella granulomatis</i> (donovanosis), human papillomavirus (HPV; genital warts/cervical cancer), <i>Sarcoptes scabiei</i> (scabies) and <i>Phthirus pubis</i> (pubic lice)	2017–2018
Phase 4	STI laboratory diagnosis and screening	2017–2018

Phase 1 will focus on treatment recommendations for specific STIs as well as other important and urgent STI issues. Recommendations for the treatment of specific infections will be developed and published as independent modules:

- *Chlamydia trachomatis* (chlamydia)
- *Neisseria gonorrhoeae* (gonorrhoea)
- HSV-2 (genital herpes)
- *Treponema pallidum* (syphilis)
- Syphilis screening and treatment of pregnant women.

In addition, guidelines for the STI syndromic approach and a clinical management package will be developed later in Phase 1. Phase 2 will focus on guidelines for STI prevention. The independent Phase 1 and 2 modules will later be consolidated into one document and published as comprehensive WHO guidelines on STI case management. Phase 3 will address treatment of additional infections, including *Trichomonas vaginalis* (trichomoniasis), bacterial vaginosis, *Candida albicans* (candidiasis), *Hemophilus ducreyi* (chancroid), *Klebsiella granulomatis* (donovanosis), HPV (genital warts/cervical cancer), *Sarcoptes scabiei* (scabies) and *Phthirus pubis* (pubic lice). Phase 4 will provide guidance on laboratory diagnosis and screening of STIs.

REFERENCES

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One*. 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304.
2. Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. *PLoS One*. 2015;10(1):e114989. doi:10.1371/journal.pone.0114989.
3. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis*. 2007;7(7):453–9.
4. Wijesooriya NS, Rochat RW, Kamb ML, Turlapati P, Broutet N, Newman L. Declines in maternal and congenital syphilis from 2008 to 2012: progress towards elimination of mother-to-child transmission of syphilis. *Lancet Global Health*. 2016 (in press).
5. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2197–223. doi:10.1016/S0140-6736(12)61689-4.
6. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. *Vaccine*. 2014;32(14):1527–35. doi:10.1016/j.vaccine.2013.07.087.
7. Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infections and other sexually transmitted diseases. *Sex Transm Dis*. 1992;19(2):61–77.
8. Sexton J, Garnett G, Røttingen J-A. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. *Sex Transm Dis*. 2005;32(6):351–7.
9. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. *AIDS*. 2009;23(12):1595–8. doi:10.1097/QAD.0b013e32832e15e8.
10. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. *Sex Transm Dis*. 2008;35(11):946–59. doi:10.1097/OLQ.0b013e3181812d15.
11. Cohen MS. Classical sexually transmitted diseases drive the spread of HIV-1: back to the future. *J Infect Dis*. 2012;206(1):1–2. doi:10.1093/infdis/jis303.
12. Progress report of the implementation of the global strategy for prevention and control of sexually transmitted infections: 2006–2015. Geneva: World Health Organization; 2015 (http://apps.who.int/iris/bitstream/10665/183117/1/9789241508841_eng.pdf, accessed 24 May 2016).
13. Ndowa FJ, Ison CA, Lusti-Narasimhan M. Gonococcal antimicrobial resistance: the implications for public health control. *Sex Transm Infect*. 2013;89(Suppl 4):iv1–2. doi:10.1136/sextrans-2013-051394.
14. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. *Vaccine*. 2014;32(14):1527–35. doi:10.1016/j.vaccine.2013.07.087.
15. Mabey D. Epidemiology of sexually transmitted infections: worldwide. *Medicine*. 2014;42(6):287–90. doi:10.1016/j.mpmed.2014.03.004.
16. Report of the expert consultation and review of the latest evidence to update guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2011 (WHO/RHR/11.37; http://apps.who.int/iris/bitstream/10665/75194/1/WHO_RHR_11.37_eng.pdf, accessed 24 May 2016).
17. Steen R. Eradicating chancroid. *Bull World Health Organ*. 2001;79(9):818–26.

01

INTRODUCTION

1.1 EPIDEMIOLOGY, BURDEN AND CLINICAL CONSIDERATIONS

Chlamydial infection, caused by *Chlamydia trachomatis*, is the most common bacterial sexually transmitted infection (STI) and results in substantial morbidity and economic cost worldwide. The World Health Organization (WHO) estimates that in 2012, 131 million new cases of chlamydia occurred among adults and adolescents aged 15–49 years worldwide, with a global incidence rate of 38 per 1000 females and 33 per 1000 males. The estimated 128 million prevalent cases of chlamydia result in an overall prevalence of 4.2% for females and 2.7% for males, with the highest prevalence in the WHO Region of the Americas and the WHO Western Pacific Region (1). In many countries, the incidence of chlamydia is highest among adolescent girls aged 15–19 years, followed by young women aged 20–24 years. The three biovars of *C. trachomatis*, each consisting of several serovars or genotypes, cause genital infections, lymphogranuloma venereum (LGV: a genital ulcer disease [GUD] that affects lymphoid tissue), and trachoma (eye infection).

CLINICAL PRESENTATION

Genital infections due to *C. trachomatis* are asymptomatic in approximately 70% of women and 50% of men (2). Symptoms of uncomplicated chlamydial infection in women include abnormal vaginal discharge, dysuria, and post-coital and intermenstrual bleeding. Common clinical signs on speculum examination include cervical friability and discharge. Symptomatic men usually present with urethral discharge and dysuria, sometimes accompanied by testicular pain. If left untreated, most genital infections will resolve spontaneously with no sequelae but they may result in severe complications, mainly in young women. Infection can ascend to the upper reproductive tract and can cause pelvic inflammatory disease, ectopic pregnancy, salpingitis and tubal factor infertility in women (3) and epididymitis in men (4). The risk of complications may increase with repeated infection.

Infections at non-genital sites are common. Rectal infection may manifest as a rectal discharge, rectal pain or blood in the stools, but is asymptomatic in most cases. Oropharyngeal infections can manifest as pharyngitis and mild sore throat, but symptoms are rare.

Chlamydial infection in pregnancy is associated with preterm birth and low birth weight. Infants of mothers with chlamydia can be infected at delivery, resulting in neonatal conjunctivitis and/or nasopharyngeal infection (3). Symptoms of ophthalmia include ocular discharge and swollen eyelids. In newborns, nasopharyngeal infection can lead to pneumonitis.

LGV, caused by a more invasive serovar of *C. trachomatis*, affects the submucosal connective tissue and can spread to regional lymph nodes. It commonly presents as a unilateral, tender inguinal or femoral lymph node and a genital ulcer or papule (5). Anorectal exposure may result in proctitis, rectal discharge, pain, constipation or tenesmus. Left untreated, LGV can lead to rectal fistula or stricture.

LABORATORY DIAGNOSIS

There have been major developments in the diagnosis of *C. trachomatis* in the last 10–20 years. Although *C. trachomatis* can be diagnosed by culture, direct immunofluorescence assays (DFAs), and laboratory-based and point-of-care enzyme-linked immunosorbent assays (ELISAs), nucleic acid amplification tests (NAATs) are strongly recommended due to their superior performance characteristics. NAATs are highly sensitive and specific and can be used for a wide range of samples, including urine and vulvovaginal, cervical and urethral swabs. Several commercial NAATs using different technologies are available. The increased sensitivity of NAATs compared with other diagnostic tests, such as culture and antigen detection methods (DFA and ELISA), allows testing of non-invasive specimens, which can be collected conveniently at the primary level of care. Commercially available NAATs are not yet licensed for the diagnosis of extra-genital samples but have shown to be reliable for detection of chlamydial infection in rectal and pharyngeal swabs. Several commercially available tests for chlamydia are combined with tests for gonorrhoea. Further information is available in the WHO publication on laboratory diagnosis of STIs including HIV (6).

1.2 RATIONALE FOR NEW RECOMMENDATIONS

The guidelines for treatment of chlamydial infections need to be updated to respond to the changes in epidemiology and antimicrobial susceptibility for chlamydia that have occurred since the previous WHO Guidelines for the management of sexually transmitted infections were published in 2003 (7). LGV is increasingly prevalent among men who have sex with men (MSM) in some settings, and treatment failure has been reported with tetracycline and macrolides in approximately 10% of cases (8). Moreover, the 2003 WHO STI guidelines are the only international guidelines that still recommend treating chlamydial infections with amoxicillin or tetracycline. As recommended by the WHO STI expert consultation in 2008, the first- and second-line treatment recommendations for *C. trachomatis* needed to be reviewed and revised based on the most recent available evidence.

1.3 OBJECTIVES

The objectives of these guidelines are:

- to provide evidence-based guidance on treatment of infection with *C. trachomatis*; and
- to support countries to update their national guidelines for treatment of chlamydial infection.

1.4 TARGET AUDIENCE

These guidelines are primarily intended for health-care providers at all levels (primary, secondary and tertiary) of the health-care system involved in the treatment and management of people with STIs in low-, middle- and high-income countries. They are also intended for individuals working in sexual and reproductive health programmes, such as HIV/AIDS, family planning, maternal and child health and adolescent health, to ensure appropriate STI diagnosis and management.

The guidelines are also useful for policy-makers, managers, programme officers and other professionals in the health sector who are responsible for implementing STI management interventions at regional, national and subnational levels.

1.5 STRUCTURE OF THE GUIDELINES

These guidelines provide evidence-based recommendations for the treatment of specific clinical conditions caused by *C. trachomatis*. These guidelines provide direction for countries as they develop national treatment recommendations; however, national guidelines should also take into account the local pattern of AMR, as well as health service capacity and resources.

Updated treatment recommendations based on the most recent evidence are included for the most important common conditions caused by *C. trachomatis*. Recommendations were not updated for rare conditions and other conditions for which no new information has become available since the 2003 WHO STI guidelines were issued.

Treatment recommendations for the following conditions caused by *C. trachomatis* are included in these guidelines:

- uncomplicated genital infections
- anorectal infections
- uncomplicated genital infections in pregnant women
- LGV
- ophthalmia neonatorum (treatment and prophylaxis).

02

METHODS

These guidelines were developed following the methods outlined in the 2014 edition of the WHO handbook for guideline development (9) (see Annex B for a detailed description).

2.1 GUIDELINE DEVELOPMENT GROUP (GDG)

To update the WHO guidelines for the prevention, treatment and management of STIs, a GDG was established, comprising 33 international STI experts, including clinicians, researchers and programme managers (Annex A). A core subgroup to focus on the guidelines related to chlamydia was created within the GDG, to provide more intensive feedback throughout the process (Annex A). The GDG participated in meetings and teleconferences to prioritize the questions to be addressed, discuss the evidence reviews and finalize the recommendations. The GDG reviewed and approved the final version of the guidelines.

2.2 QUESTIONS AND OUTCOMES

In December 2013 the first GDG meeting was held to identify and agree on the key PICO (population, intervention, comparator, outcome) questions that formed the basis for the systematic reviews and the recommendations. Following this meeting, a survey of GDG members was conducted to prioritize the questions and outcomes according to clinical relevance and importance. Six PICO questions were identified for the update on the treatment of genital and anorectal chlamydial infections, treatment of LGV, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations, namely adolescents, pregnant women, people living with HIV, and populations at high risk of acquiring and transmitting STIs, such as men who have sex with men (MSM) and sex workers. Only outcomes that were ranked as critical or important to patients and decision-making were included: clinical and microbiological cure, and adverse effects (including maternal and fetal effects in pregnant women).

2.3 REVIEWS OF THE EVIDENCE

The systematic reviews for each priority question were conducted by McMaster University, the WHO Collaborating Centre for Evidence-Informed Policy. Evidence for desirable and undesirable outcomes, patient values and preferences, resources, acceptability, equity and feasibility were reviewed from published and unpublished literature. Comprehensive searches for previously conducted systematic reviews, randomized controlled trials and non-randomized studies were performed from March to October 2015. Additional searches were conducted to identify studies on patient values and preferences (e.g. qualitative research designs) and resource implications (e.g. cost of interventions, cost-benefit and cost-effectiveness studies). Two members of the Systematic Review Team screened studies, extracted and analysed the data, and assessed the quality/certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.¹

1 For more information, see: <http://www.gradeworkinggroup.org/>

The quality/certainty of the evidence was assessed at four levels:

- High – We are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate – We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
- Low – Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
- Very low – We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

In addition, the direct costs of medicines were estimated using the 2014 Management Sciences for Health (MSH) International drug price indicator guide (10). References for all the reviewed evidence are listed in Annex C. All evidence was summarized in GRADE evidence profiles and in evidence-to-decision tables (see Web annexes D and E).

2.4 MAKING RECOMMENDATIONS

Recommendations were developed during a second meeting of the GDG in October 2015, which was facilitated by two co-chairs, one with expertise in GRADE and the other with clinical STI expertise. The methodologist presented the GRADE evidence profiles and evidence-to-decision frameworks at the meeting. When formulating the recommendations, the GDG considered and discussed the desirable and undesirable effects of the interventions, the value placed on the outcomes, the associated costs and use of resources, the acceptability of the interventions to all stakeholders (including people affected by STIs), the impact on health equity and the feasibility of implementation. Treatments were judged according to the above criteria and final decisions and guideline recommendations were agreed. The discussion was facilitated by the co-chairs with the goal of reaching consensus across the GDG. Disagreements among the GDG members were noted in the evidence-to-decision framework for each judgement. In the case of failure to reach consensus for a recommendation, the planned procedure was for the GDG to take a vote and record the results. However, no votes were taken because the GDG reached consensus during discussion for all

of the recommendations. Following the meeting, the recommendations were finalized via teleconference and final approval was obtained from all GDG members electronically. These guidelines were subsequently written up in full and then peer reviewed. The External Review Group approved the methods and agreed with the recommendations made by the GDG (members are listed in Annex A).

According to the GRADE approach, the strength of each recommendation was rated as either strong or conditional. Strong recommendations are presented using the wording “The WHO STI guideline recommends...”, while conditional recommendations are worded as “The WHO STI guideline suggests...” throughout the guidelines. The implications of the differing strengths of recommendations for patients, clinicians and policy-makers are explained in detail in Table 3.

Table 3. Implications of strong and conditional recommendations using the GRADE approach

Implications	Strong recommendation “The WHO STI guideline recommends...”	Conditional recommendation “The WHO STI guideline suggests...”
For patients	Most individuals in this situation would want the recommended course of action, and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.	The majority of individuals in this situation would want the suggested course of action, but many would not.
For clinicians	Most individuals should receive the recommended course of action. Adherence to this recommendation according to the guidelines could be used as a quality criterion or performance indicator.	Clinicians should recognize that different choices will be appropriate for each individual and that clinicians must help each individual arrive at a management decision consistent with the individual's values and preferences. Decision aids may be useful to help individuals make decisions consistent with their values and preferences.
For policy-makers	The recommendation can be adopted as policy in most situations.	Policy-making will require substantial debate and involvement of various stakeholders.

2.5 MANAGEMENT OF CONFLICTS OF INTEREST

Management of conflicts of interest was a key priority throughout the process of guideline development. WHO guidelines for declaration of interests (DOI) for WHO experts were implemented (11). DOI statements were obtained from all GDG members prior to assuming their roles in the group. At the GDG meetings (December 2013 and October 2015), the members disclosed their interests, if any, at the beginning of the meeting. Their DOI statements are summarized in Web annex F.

After analysing each DOI, the STI team concluded that no member had financial or commercial interests related to STI treatment. Other notified interests were minor; they were either not related to STI or were non-commercial grants or interests. The STI team concluded that there were no significant conflicts of interest that would exclude any member from participating fully in the guideline development process. Therefore, options for conditional participation, partial or total exclusion of any GDG member were not discussed.

03

DISSEMINATION,
UPDATING AND
IMPLEMENTATION OF
THE GUIDELINES**3.1 DISSEMINATION**

These guidelines will be made available as a printed publication, as a download on the website of the WHO Department of Reproductive Health and Research (where there will also be links to all supporting documentation)², and in the WHO Reproductive Health Library (RHL)³. The recommendations will also be available in a guideline application (“app”) created with the GRADEpro GDT software. The guidelines will be announced in the next edition of the RHL newsletter and in the Reproductive Health and Research departmental newsletter, and other relevant organizations will be requested to copy the announcement in their respective newsletters.

WHO headquarters will work with WHO’s regional offices and country offices to ensure that countries receive support in the adaptation, implementation and monitoring of these guidelines using the WHO Department of Reproductive Health and Research guidance on Introducing WHO’s reproductive health guidelines and tools into national programmes (12).

All levels of WHO (headquarters, regional offices and country offices) will work with regional and national partners – including the United Nations Population Fund (UNFPA), the United Nations Children’s Fund (UNICEF), the Joint United Programme on HIV/AIDS (UNAIDS), nongovernmental organizations (NGOs) and other agencies implementing sexual and reproductive health and STI services – to ensure that the new recommendations are integrated and implemented in sexual and reproductive health, family planning, and maternal, neonatal, child and adolescent health services. Reference to this document will be made within other relevant WHO guidelines. These guidelines will also be disseminated at major conferences related to STIs and HIV and the aforementioned programme areas.

3.2 UPDATING THE GUIDELINES AND USER FEEDBACK

A system of monitoring relevant new evidence and updating the recommendations as new findings become available will be established within a year of implementing the guidelines. An electronic follow-up survey of key end-users of the STI guidelines will be conducted after the release of the guidelines. The results of the survey will be used to identify challenges and barriers to the uptake of the guidelines, to evaluate their usefulness for improving service delivery, and to identify topics or gaps in treatment that need to be addressed in future editions.

3.3 IMPLEMENTATION OF THE WHO GUIDELINES FOR THE TREATMENT OF C. TRACHOMATIS**ADAPTATION, IMPLEMENTATION AND MONITORING**

These guidelines provide recommendations for treatment of chlamydial infection based on the best global evidence available at the time of compilation. However, the epidemiology and AMR of STIs vary by geographical location and are constantly changing, sometimes rapidly. It is recommended that countries conduct good quality studies to gather the information needed to adapt these guidelines to the local STI situation as they update their national guidelines. In areas lacking local data as a basis for adaptation, the recommendations in these guidelines can be adopted as presented.

² These guidelines and all supporting documents will be available at: www.who.int/reproductivehealth/publications/rtis/chlamydia-treatment-guidelines/en/

³ RHL is available at: <http://apps.who.int/rhl/en/>

For further guidance on adaptation, implementation and monitoring of national guidelines please refer to **Introducing WHO's reproductive health guidelines and tools into national programmes: principles and processes of adaptation and implementation (12)**.

In adapting the guidelines for national use, recommended treatments should have an efficacy of at least 95%. The criteria to be considered for the selection of medicines are listed in Box 1. Recommended medicines should meet as many of the criteria as possible, taking into account local availability, efficacy, route and frequency of administration.

BOX 1. CRITERIA FOR THE SELECTION OF MEDICINES FOR THE TREATMENT OF STIS

- High efficacy (at least 95% cure rate)
- High quality (potent active ingredient)
- Low cost
- Low toxicity levels
- Organism resistance unlikely to develop or likely to be delayed
- Single dose
- Oral administration
- Not contraindicated for pregnant or lactating women

Appropriate medicines should be included in the national essential medicines lists. When selecting medicines, consideration should be given to the competencies and experience of health-care providers.

In order to estimate the quantity of medicines needed, it will be necessary to review the medicines that are recommended for treatment, their unit prices, the quantity required per treatment and the epidemiological information on the prevalence of infection. One can estimate medicine needs by multiplying the estimated number of cases by the total quantity of medicine specified for treatment of one case. These figures can be derived from health centres providing care but they must be verified to avoid wasteful over-ordering.

Budgeting for medicines is critical. If the national ministry of health does not provide medicines for free and the patient cannot afford to buy the medicines, then there will essentially be no possibility of curtailing the spread of infection and the occurrence of complications. At the national level it is important that decision-makers, politicians and fiscal controllers understand the need to subsidize STI medicines. Low-cost STI medicines can be obtained through international vendors of generic products, non-profit organizations with procurement schemes such as UNICEF, UNFPA and UNHCR, and through joint medicine procurement schemes. By way of such schemes, national programmes can join other national programmes to jointly procure medicines, thus reducing the overall costs by sharing the overhead costs and taking advantage of discounts for purchasing in bulk. Placing STI medicines on national lists of essential medicines increases the likelihood of achieving a supply of these medicines at low cost.

IDENTIFYING AND PROCURING STI DRUGS

It is important not only to identify medicines that will be recommended as first-line treatment for STIs but also the estimated quantities of the medicines that will be required. Quantifying medication needs is important in order to estimate costs, to reconcile financial requirements with available budget, and to make orders in advance so that the unit and freight costs can be minimized.

04

RECOMMENDATIONS
FOR TREATMENT
OF CHLAMYDIAL
INFECTIONS

The following nine recommendations apply to adults, adolescents (10–19 years of age), people living with HIV, and key populations, including sex workers, men who have sex with men (MSM) and transgender persons. Specific recommendations have also been developed for ophthalmia neonatorum caused by *C. trachomatis*.

4.1 UNCOMPLICATED GENITAL CHLAMYDIA

RECOMMENDATION 1

For people with uncomplicated genital chlamydia, the WHO STI guideline suggests one of the following options:

- azithromycin 1 g orally as a single oral dose
- doxycycline 100 mg orally twice a day for 7 days

or one of these alternatives:

- tetracycline 500 mg orally four times a day for 7 days
- erythromycin 500 mg orally four times a day for 7 days
- ofloxacin 200–400 mg orally twice a day for 7 days.

Conditional recommendation, moderate quality evidence

Remarks: While good practice based on evidence of large net benefit dictates that patients should be treated for chlamydial infection, the choice of treatment may depend on the convenience of dosage, the cost and quality of the medicines in different settings, and equity considerations. When high value is placed on reducing costs, doxycycline in a standard dose may be the best choice; when high value is placed on convenience, azithromycin in a single dose may be the best choice. A delayed-release formulation of doxycycline may be an alternative to twice daily dosing of doxycycline, but the high cost of the delayed-release formulation may prohibit its use. Note that doxycycline, tetracycline and ofloxacin are contraindicated in pregnant women (see recommendations 3a–3c).

Research implications: The potential for resistance to azithromycin, doxycycline and other treatment options should be investigated. Future research could compare these treatments and recommended dosages in randomized controlled trials measuring important outcomes such as clinical cure, microbiological cure, complications, side-effects (including allergy, toxicity, gastrointestinal effects), compliance, quality of life, HIV transmission and acquisition, and partner transmission of chlamydia. Studies are also needed that evaluate amoxicillin (500 mg three times a day for 7 days).

SUMMARY OF THE EVIDENCE

Evidence from a Cochrane systematic review was used. This review included 25 randomized studies comparing tetracycline, quinolones and macrolides. There are no data available for amoxicillin. Overall, there is moderate to low quality evidence for most comparisons of treatments. Moderate quality evidence shows trivial differences between azithromycin 1 g and doxycycline 100 mg orally twice a day for 7 days in the numbers of people microbiologically cured and experiencing adverse events. There were 10 fewer people per 1000 cured with azithromycin versus doxycycline, ranging from 38 fewer to 10 more (risk ratio [RR] 0.99; 95% confidence interval [CI] 0.96 to 1.10). In addition, there were 3 more adverse events per 1000 people with azithromycin versus doxycycline, ranging from 42 fewer to 64 more (RR 1.02; 95% CI 0.72 to 1.43). Similar results are shown in a recently published randomized study. Delayed-release doxycycline hyclate probably leads to little to no difference in the proportion of people microbiologically cured but probably has fewer side-effects than standard dose doxycycline. Ofloxacin may result in fewer cures but also slightly fewer adverse events compared to doxycycline. When comparing multiple high doses of azithromycin (1 g weekly for 3 weeks) to a single dose, more people may be cured but

there are no data for adverse events related to very high doses. Higher doses of any tetracycline compared with lower doses may lead to more cures but will probably also lead to more adverse events. Tetracyclines compared with quinolones may lead to fewer cures but also slightly fewer adverse events. Erythromycin compared with quinolones may lead to fewer cures and more adverse events.

There is no evidence relating to patient values and preferences but the Guideline Development Group (GDG) agreed that there is probably no variability in the values people place on the outcomes. Research related to other conditions indicates that adherence may be improved with simpler medication regimens. The GDG therefore agreed that azithromycin may be more acceptable to patients since it is a single dose regimen (a majority of the GDG members considered single-dose regimens to be preferable for patient compliance over multi-dose regimens). There is little to no evidence for equity issues and feasibility. Resistance in other infections (e.g. gonorrhoea and *Mycoplasma genitalium*) that often co-occur with chlamydia may restrict the use of some medicines, such as ofloxacin. For many of these medicines, costs may differ between countries; in places with high incidence of chlamydia, the cost differences between azithromycin and doxycycline may be large due to greater numbers of people requiring treatment.

In summary, there was moderate quality evidence for trivial differences in benefits and harms between azithromycin and doxycycline, and although the cost of azithromycin is higher, the single dose may make it more convenient to use than doxycycline. While the differences are also trivial with the other medicines, the evidence is low quality and these are therefore provided as alternatives, with the exception of delayed-release doxycycline, which is currently expensive.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 3–22).

4.2 ANORECTAL CHLAMYDIAL INFECTION

RECOMMENDATION 2

In people with anorectal chlamydial infection, the WHO STI guideline suggests using doxycycline 100 mg orally twice daily for 7 days over azithromycin 1 g orally single dose.

Conditional recommendation, low quality evidence

Remarks: This recommendation applies to people with known anorectal infection and to people with suspected anorectal infections with genital co-infection. Clinicians should ask men, women and key populations (e.g. men who have sex with men [MSM], transgender persons and female sex workers) about anal sex and treat accordingly. Doxycycline should not be used in pregnant women because of adverse effects (see recommendations 3a–3c).

Research implications: The global incidence of chlamydial anorectal infections should be determined. More research is necessary on the effects of treatments used for anorectal infections, particularly azithromycin, which is currently not on the WHO essential medicines list for anorectal chlamydial infections (13). Effects should be assessed in both men and women, and in key populations (e.g. MSM, transgender persons and female sex workers).

SUMMARY OF THE EVIDENCE

There is low quality evidence from eight non-randomized studies (five direct comparisons and three single-arm studies) that evaluated doxycycline and azithromycin (see Web annexes D and E). There are no data for amoxicillin, erythromycin and quinolones. Evidence showed that there may be 200 fewer microbiological cures per 1000 people with azithromycin compared with doxycycline (RR 0.80; 95% CI 0.71 to 0.91). Evidence from studies of genital infections shows little to no difference in side-effects with these treatments (RR 1.02; 95% CI 0.72 to 1.43). Although there are fewer women than men in the studies, the evidence suggested little difference in effects between men and women. There is no evidence relating to patient values and preferences, but the GDG agreed that there are no known reasons to suspect values would vary for different people. There is little to no evidence for acceptability, but research in other conditions indicates that adherence may be improved with simpler medication regimens. There is also little to no evidence for equity issues and feasibility, but azithromycin is more expensive and typically the cost is transferred to consumers. The GDG agreed that equity may vary between the medicines depending on the population: in some populations, azithromycin may be more acceptable since it is a single-dose treatment, and some people may experience stigma related to visibility of a multi-dose regimen with doxycycline. Therefore, suggesting doxycycline over azithromycin could create inequity for people sensitive to stigma related to multi-dose regimens. Azithromycin is currently not listed as an essential medicine for anorectal chlamydial infection.

In summary, doxycycline may result in more cures, but although it is less expensive than azithromycin, azithromycin may be better accepted due to the single-dose treatment.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 23-35).

4.3 CHLAMYDIAL INFECTION IN PREGNANT WOMEN

RECOMMENDATION 3A

In pregnant women with genital chlamydial infection, the WHO STI guideline recommends using azithromycin over erythromycin.

Strong recommendation, moderate quality evidence

RECOMMENDATION 3B

In pregnant women with genital chlamydial infection, the WHO STI guideline suggests using azithromycin over amoxicillin.

Conditional recommendation, low quality evidence

RECOMMENDATION 3C

In pregnant women with genital chlamydial infection, the WHO STI guideline suggests using amoxicillin over erythromycin.

Conditional recommendation, low quality evidence

Dosages:

- azithromycin 1 g orally as a single dose
- amoxicillin 500 mg orally three times a day for 7 days
- erythromycin 500 mg orally four times a day for 7 days.

Remarks: Azithromycin is the first choice of treatment but may not be available in some settings. Azithromycin is less expensive than erythromycin and since it is provided as a single dose, may result in better adherence and therefore better outcomes.

Research implications: Research in pregnant women comparing these treatments and the recommended dosages should be conducted. Although these medicines are relatively safe in pregnancy, maternal and fetal complications (e.g. adverse pregnancy outcomes, fetal defects) with the use of these treatments for STIs and other infections should be monitored, collected and analysed to inform updated recommendations in the future. When conducting these studies, costs and acceptability of the treatments could be measured.

SUMMARY OF THE EVIDENCE

Overall, there is moderate to low quality evidence from 14 randomized controlled trials, two non-randomized comparative studies and two large cohort studies assessing the effects of azithromycin, erythromycin and amoxicillin in pregnant women with chlamydial infections. The differences in benefits between these different treatments are small, and wide confidence intervals included the possibility of greater or lesser benefits with azithromycin compared to other medicines. Moderate quality evidence found that there are probably 94 more people microbiologically cured per 1000 with azithromycin versus erythromycin (RR 1.11; 95% CI 0.94 to 1.30), and low-quality evidence found that there may be 72 more people cured per 1000 with azithromycin versus amoxicillin (RR 1.09, 95% CI 0.93 to 1.28). There are probably 40 fewer people microbiologically cured per 1000 with erythromycin versus amoxicillin (RR 0.95; 95% CI 0.88 to 1.02). There may be slightly fewer side-effects with azithromycin compared with erythromycin or amoxicillin (approximately 50/1000 fewer), but there may be substantially more side-effects with erythromycin versus amoxicillin (approximately 400/1000 more).

Much of the evidence was uncertain for fetal outcomes as it came from indirect comparisons in large cohort studies. There were few events, and confidence intervals around the small differences included the potential for fewer or more events between comparisons.

In summary, the GDG agreed that azithromycin is preferred over erythromycin because of greater effectiveness and lower cost, and preferred over amoxicillin due to greater effectiveness. Azithromycin may also be more acceptable due to single dosage; however, it may not be available in all settings due to misconceptions that it is costly. Amoxicillin is preferred over erythromycin as it is less costly and may result in greater benefits and fewer side-effects.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 36-51).

4.4 LYMPHOGRANULOMA VENEREUM (LGV)

RECOMMENDATION 4

In adults and adolescents with LGV, the WHO STI guideline suggests using doxycycline 100 mg orally twice daily for 21 days over azithromycin 1 g orally, weekly for 3 weeks.

Conditional recommendation, very low quality evidence

Remarks: Good practice dictates treatment of LGV, in particular for men who have sex with men (MSM) and for people living with HIV. When doxycycline is contraindicated, azithromycin should be provided. When neither treatment is available, erythromycin 500 mg orally four times a day for 21 days is an alternative. Doxycycline should not be used in pregnant women because of adverse effects (see recommendations 3a–3c).

Research implications: Additional research for each of the treatments and the dosages recommended is needed, in particular for erythromycin and azithromycin. Randomized controlled trials should be conducted, measuring critical and important outcomes, such as clinical cure, microbiological cure, complications, side-effects (including allergy, toxicity, gastrointestinal effects), quality of life, HIV transmission and acquisition, compliance and LGV transmission to partners. The effects of shorter courses of treatment should also be investigated.

SUMMARY OF THE EVIDENCE

There is very low quality evidence from 12 non-randomized studies with no comparisons between treatments. These studies assessed treatment with azithromycin and doxycycline for 21 days, and erythromycin for 14 days. Evidence for doxycycline showed that there may be large benefits (clinical and microbiological cure rates greater than 90%) and trivial side-effects (e.g. persistent mucous membrane abnormalities, perirectal abscess and allergy). The effects of azithromycin and erythromycin were uncertain, with only 14 people receiving azithromycin and 31 people receiving erythromycin in the studies. Side-effects are likely trivial and similar to the side-effects of these treatments in people with other chlamydial infections. There is no evidence relating to patient values and preferences, but the GDG agreed that there are no known reasons to suspect values would vary for different people. There is little to no evidence for acceptability, but research in other conditions indicates that adherence may be improved with simpler medication regimens. There is little evidence for equity issues and feasibility, but the GDG

agreed that these may be dependent on individuals and countries. Data for medicine prices and procurement indicate that doxycycline is cheaper than azithromycin and erythromycin, although the latter medicines are still inexpensive.

In summary, there is very low quality evidence for all medicines for treatment of LGV. The evidence suggests large benefits with doxycycline over azithromycin, and the effects of erythromycin are unknown. In addition, doxycycline is the least expensive.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 52–63).

4.5 OPHTHALMIA NEONATORUM

RECOMMENDATION 5

In neonates with chlamydial conjunctivitis, the WHO STI guideline recommends using oral azithromycin 20 mg/kg/day orally, one dose daily for 3 days, over erythromycin 50 mg/kg/day orally, in four divided doses daily for 14 days.

Strong recommendation, very low quality evidence

Remarks: This is a strong recommendation given the potential for the risk of pyloric stenosis with the use of erythromycin in neonates. In some settings, azithromycin suspension is not available and therefore erythromycin may be used. Side-effects should be monitored with the use of either medication.

Research implications: Additional research should be conducted to determine the effects of these medicines to treat ophthalmia neonatorum. The effects of other medications such as trimethoprim should also be investigated. Pyloric stenosis should be monitored or research conducted to evaluate this risk with the medicines suggested.

SUMMARY OF THE EVIDENCE

There is low quality evidence for a cure rate of 98% with erythromycin 50 mg/kg/day for 14 days, and uncertain effects on the cure rate for azithromycin given the small numbers of neonates receiving azithromycin in the study (see Web annexes D and E). There is very low quality evidence for 7 more instances of pyloric stenosis per 1000 with erythromycin. The GDG regarded the risk of pyloric stenosis as a serious adverse effect of erythromycin use in children. There are no data evaluating pyloric stenosis due to use of azithromycin. There are also no data assessing the effects of

trimethoprim. There is no evidence for variation in patient values and preferences, but compliance with treatments ranged from 77% to 89%. The costs for treatments are relatively low and similar, and most treatments are currently being used.

In summary, azithromycin is preferred over erythromycin because of the potential risk of serious adverse events with erythromycin, and there are no data for trimethoprim.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 64-74).

RECOMMENDATION 6

For all neonates, the WHO STI guideline recommends topical ocular prophylaxis for the prevention of gonococcal and chlamydial ophthalmia neonatorum.

Strong recommendation, low quality evidence

RECOMMENDATION 7

For ocular prophylaxis, the WHO STI guideline suggests one of the following options for topical application to both eyes immediately after birth:

- tetracycline hydrochloride 1% eye ointment
- erythromycin 0.5% eye ointment
- povidone iodine 2.5% solution (water-based)
- silver nitrate 1% solution
- chloramphenicol 1% eye ointment.

Conditional recommendation, low quality evidence

Remarks: Recommendations 6 and 7 apply to the prevention of both chlamydial and gonococcal ophthalmia neonatorum. Cost and local resistance to erythromycin, tetracycline and chloramphenicol in gonococcal infection may determine the choice of medication. Caution should be taken to avoid touching eye tissue when applying the topical treatment and to provide a water-based solution of povidone iodine. Alcohol-based povidone iodine solution must not be applied. The topical application should be administered immediately after birth.

Research implications: The prevalence of gonococcal ophthalmia should be determined given the high prevalence of maternal gonorrhoea in some settings. The state of resistance to the medications should be explored and it should be established whether these organisms would be killed by ocular prophylaxis despite resistant strains being established in the organisms. More research comparing the benefits and harms of the different medications is needed, in particular comparisons with chloramphenicol.

SUMMARY OF THE EVIDENCE

Overall, the quality of evidence is low to very low from 16 studies: 15 randomized studies and one non-randomized study with two comparison groups. There are few available data for the effects of chloramphenicol. Large benefits were reported for prophylaxis compared with no prophylaxis, in particular in babies born to women with known infection (approximately 70% reduction in conjunctivitis with prophylaxis using different medications). The benefits with different medications are similar; however, the low to very low quality evidence indicates that the benefits of tetracycline hydrochloride, erythromycin or povidone iodine may be slightly greater than for silver nitrate.

Few data are available for the incidence of non-infectious conjunctivitis after prophylaxis or no prophylaxis. Low quality evidence shows a slight reduction or little difference and indicates that between 4 and 50 per 1000 infants have non-infectious conjunctivitis after application of different prophylactic medications. There is little evidence relating to patient values and preferences, but the GDG agreed that there would likely be little difference in the high value placed on avoiding long-term consequences of both gonococcal and chlamydial conjunctivitis. The GDG also agreed that there would be little effect on acceptability, equity and feasibility, as prophylaxis is currently used in many countries. The GDG reported that alcohol-based povidone iodine has erroneously been used as prophylaxis resulting in serious harm to babies. Silver nitrate is the most expensive prophylaxis option.

In summary, there are large benefits for prophylaxis to prevent ophthalmia neonatorum, and these benefits outweigh the risk of non-infectious conjunctivitis due to prophylaxis with any of the topical medications. Some topical medications may provide greater protection (tetracycline hydrochloride, erythromycin or povidone iodine), but all are feasible to provide.

See Annex C for list of references of reviewed evidence, and Web annex D for details of the evidence reviewed, including evidence profiles and evidence-to-decision frameworks (pp. 75-96).

REFERENCES

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One*. 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304.
2. Harryman L, Blee K, Horner P. *Chlamydia trachomatis* and non-gonococcal urethritis. *Medicine*. 2014;42(6):327–332. doi:10.1016/j.jmpmed.2014.03.001.
3. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after *Chlamydia trachomatis* genital infection in women. *J Infect Dis*. 2010;201(Suppl 2):S134–55. doi:10.1086/652395.
4. Bébéar C, de Barbeyrac B. Genital *Chlamydia trachomatis* infections. *Clin Microbiol Infect*. 2009;15(1):4–10. doi:10.1111/j.1469-0691.2008.02647.x.
5. Herring A, Richens J. Lymphogranuloma venereum. *Sex Transm Infect*. 2006;82(Suppl 4):iv23–5. doi:10.1136/sti.2006.023143.
6. Laboratory diagnosis of sexually transmitted infections including human immunodeficiency virus. Geneva: World Health Organization; 2013 (http://apps.who.int/iris/bitstream/10665/85343/1/9789241505840_eng.pdf, accessed 24 May 2016).
7. Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2003 (<http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf>, accessed 25 May 2016).
8. Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. *Clin Infect Dis*. 2013;56(7):934–42. doi:10.1093/cid/cis1022.
9. WHO handbook for guideline development, 2nd edition. Geneva: World Health Organization; 2014 (http://www.who.int/kms/handbook_2nd_ed.pdf, accessed 25 May 2016).
10. Management Sciences for Health (MSH) and World Health Organization (WHO). International drug price indicator guide, 2013 edition (updated annually). Medford (MA): MSH; 2014 (<http://apps.who.int/medicinedocs/documents/s21497en/s21497en.pdf>, accessed 24 May 2016).
11. WHO guidelines for declaration of interests (WHO experts). Geneva: World Health Organization; 2014.
12. Introducing WHO's reproductive health guidelines and tools into national programmes: principles and processes of adaptation and implementation. Geneva: World Health Organization; 2007 (http://whqlibdoc.who.int/hq/2007/WHO_RHR_07.9_eng.pdf, accessed 25 May 2016).
13. WHO essential medicines list, 19th edition. Geneva: World Health Organization; 2015 (http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf, accessed 24 May 2016).

ANNEX A: STI GUIDELINE DEVELOPMENT TEAMS

WHO STI STEERING COMMITTEE

WHO regional STI focal points		Region
1.	Massimo Ghidinelli	Region of the Americas (AMR) Washington, DC – United States of America (USA)
2.	Lali Khotenashvili	European Region (EUR) Copenhagen – Denmark
3.	Ying-Ru Lo	Western Pacific Region (WPR) Manila – Philippines
4.	Frank Lule	African Region (AFR) Brazzaville – Congo
5.	Razia Pendse and Ornella Lincetto	South-East Asia Region (SEAR) New Delhi – India WHO Country Representative, Bhutan
6.	Hamida Khattabi and Gabriela Reidner	Eastern Mediterranean Region (EMR) Cairo – Egypt
WHO headquarters		Department and Team
7.	Moazzam Ali	Department of Reproductive Health and Research Human Reproduction Team
8.	Avni Amin	Department of Reproductive Health and Research Adolescents and at-Risk Populations
9.	Rachel Baggaley	Department of HIV/AIDS Key Populations and Innovative Prevention
10.	Venkatraman Chandra-Mouli	Department of Reproductive Health and Research Adolescents and at-Risk Populations
11.	Jane Ferguson	Department of Maternal, Newborn, Child and Adolescent Health; Research and Development
12.	Mario Festin	Department of Reproductive Health and Research Human Reproduction Team
13.	Mary Lyn Gaffield	Department of Reproductive Health and Research Human Reproduction Team
14.	Antonio Gerbase	Department of HIV/ AIDS Key populations and Innovative Prevention
15.	Sami Gottlieb	Department of Reproductive Health and Research Human Reproduction Team
16.	Silvo Paolo Mariotti	Department of Noncommunicable Disease and Mental Health Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention Blindness Deafness Prevention, Disability and Rehabilitation
17.	Frances McConville	Department of Maternal, Newborn, Child and Adolescent Health

18.	Lori Newman	Department of Reproductive Health and Research Human Reproduction Team
19.	Annette Mwansa Nkowane	Department of Health Workforce
20.	Anita Sands	Essential Medicines and Health Products, Prequalification Team
21.	Igor Toskin	Department of Reproductive Health and Research Human Reproduction Team
22.	Marco Vitoria	Department of HIV/AIDS Treatment and Care
WHO STI Secretariat		Department and Team
23.	Ian Askew	Department of Reproductive Health and Research Human Reproduction Team
24.	Nathalie Broutet (co-lead of the development process)	Department of Reproductive Health and Research Human Reproduction Team
25.	James Kiarie	Department of Reproductive Health and Research Human Reproduction Team
26.	Lee Sharkey	Department of Reproductive Health and Research Human Reproduction Team
27.	Teodora Elvira Wi (lead of the development process)	Department of Reproductive Health and Research Human Reproduction Team

METHODOLOGIST

Nancy Santesso

Department of Clinical Epidemiology and Biostatistics
McMaster University
1200 Main Street West
Hamilton, Ontario L8N 3Z5
Canada

SYSTEMATIC REVIEW TEAM: MCMASTER UNIVERSITY

Team lead: Nancy Santesso

Team members: Housne Begum, Janna-Lina Kerth,
Gian Paolo Morgano, Kristie Poole, Nicole Schwab,
Matthew Ventresca, Yuan Zhang, Andrew Zikic

STI GUIDELINE DEVELOPMENT GROUP

Chairpersons: Judith Wasserheit, Holger Schünemann, Patricia Garcia

	Name and address	Region	Sex
1.	Yaw (Sax) Adu-Sarkodie School of Medical Sciences Kwame Nkrumah University of Science and Technology (KNUST) PO Box 1934, Bantama Kumasi Ghana	AFR	M
2.	Andrew Amato European Centre for Disease Prevention and Control Tomtebodavägen 11a 171 83 Stockholm Sweden	EUR	M
3.	Gail Bolan Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333 USA	AMR	F
4.	John Chungalucha National Institute for Medical Research Mwanza Medical Research Centre PO Box 1462 Mwanza Tanzania	AFR	M
5.	Xiang-Sheng Chen National Center for STD Control Chinese Academy of Medical Sciences and Peking Union Medical College 12 Jiangwangmiao Street Nanjing 210042 China	WPR	M
6.	Harrel Chesson Division of STI Prevention Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333 USA	AMR	M
7.	Craig Cohen University of California, San Francisco 50 Beale Street, Suite 1200 San Francisco, CA 94117 USA	AMR	M
8.	Francisco Garcia Pima County Health Department 3950 S. Country Club Road Suite 100 Tucson, AZ 85714 USA	AMR	M

9.	Patricia Garcia (Co-Chair) School of Public Health and Administration Universidad Peruana Cayetano Heredia Ave Honorio Delgado 430 31 AP, 4314 Lima Peru	AMR	F
10.	Suzanne Garland Royal Women's Hospital, Level 1 Bldg 404, Bio 21 Institute 30 Flemington Road, Parkville Victoria Australia	WPR	F
11.	Sarah Hawkes University College London Institute for Global Health London United Kingdom	EUR	F
12.	Mary Higgins International Confederation of Midwives Laan van Meerdervoort 70 2517 AN The Hague The Netherlands	EUR	F
13.	King Holmes Department of Global Health and Department of Medicine University of Washington Harborview Medical Center 325 9th Ave., Box 359931 Seattle, WA 98104 USA	AMR	M
14.	Jeffrey Klausner Division of Infectious Diseases and Program in Global Health David Geffen School of Medicine and Fielding School of Public Health University of California, Los Angeles USA	AMR	M
15.	David Lewis Western Sydney Sexual Health Centre Marie Bashir Institute for Infectious Diseases and Biosecurity Sydney Medical School Westmead, University of Sydney Sydney Australia	WPR	M
16.	Nicola Low Epidemiology and Public Health University of Bern Institute of Social and Preventive Medicine Finkenhubelweg 11 3012 Bern Switzerland	EUR	F
17.	David Mabey Communicable Diseases London School of Hygiene and Tropical Medicine (LSHTM) Keppel Street London WC1E 7HT United Kingdom	EUR	M

18.	Angelica Espinosa Miranda Núcleo de Doenças Infecciosas Universidade Federal do Espírito Santo Av. Marechal Campos 1468 Maruípe Vitória – ES CEP 29040-091 Brazil	AMR	F
19.	Nelly Mugo Kenya Medical Research Institute Mbagathi Rd. PO Box 54840 - 00200 Nairobi Kenya	AFR	F
20.	Saiqa Mullick Implementation Science University of the Witwatersrand Hillbrow Health Precinct Hillbrow, Johannesburg South Africa	AFR	F
21.	Francis Ndowa 6 Thames Road Vainona, Harare Zimbabwe	AFR	M
22.	Joel Palefsky Division of Infectious Diseases Box 0654 513 Parnassus Ave, Room S420 University of California, San Francisco San Francisco, CA 94143 USA	AMR	M
23.	Keith Radcliffe European STI Guidelines Project International Union against Sexually Transmitted Infections (IUSTI) Royal Society of Medicine 1 Wimpole Street London W1G 0AE United Kingdom	EUR	M
24.	Ulugbek Sabirov National STI Program Republican Center for Dermato-Venereology Tashkent Uzbekistan	EUR	M
25.	Holger Schünemann (Co-Chair) Department of Clinical Epidemiology and Biostatistics McMaster University 1200 Main Street West Hamilton, Ontario L8N 3Z5 Canada	AMR	M
26.	Richard Steen Località Cassaluvo Diano San Pietro Imperia 18013 Italy	EUR	M

27.	Judith Stephenson University College London Gower Street London United Kingdom	EUR	F
28.	Magnus Unemo Department of Laboratory Medicine Microbiology Örebro University Hospital SE-701 85 Örebro Sweden	EUR	M
29.	Bea Vuylsteke Institute of Tropical Medicine Nationalestraat 155 2000 Antwerp Belgium	EUR	F
30.	Anna Wald University of Washington Virology Research Clinic Harborview Medical Center 325 9th Ave, Box 359928 Seattle, WA 98104 USA	AMR	F
31.	Judith Wasserheit (Co-Chair) Department of Global Health Professor of Global Health and Medicine Adjunct Professor of Epidemiology University of Washington Harris Hydraulics Building, Room 309D 1705 NE Pacific Street Box 357965 Seattle, WA 98195-7965 USA	AMR	F
32.	Thomas Wong Division of Community Acquired Infections Centre for Communicable Diseases and Infection Control Public Health Agency of Canada Room 2391, 100 Eglantine Driveway Tunney's Pasture, AL 0602C Ottawa, Ontario K1A 0L2 Canada	AMR	M
33.	Kimberly A. Workowski Centers for Disease Control and Prevention (CDC) Division of Infectious Diseases Emory University School of Medicine 1600 Clifton Rd. Atlanta, GA 30333 USA	AMR	F

AFR: WHO African Region; AMR: WHO Region of the Americas; EMR: WHO Eastern Mediterranean Region;
EUR: WHO European Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region

STI Guideline Development Group: Working group for chlamydia

1.	Andrew Amato
2.	Harrell Chesson
3.	Craig Cohen
4.	Patricia Garcia
5.	Nicola Low
6.	David Mabey
7.	Angelica Miranda
8.	Francis Ndowa
9.	Keith Radcliffe
10.	Judith Stephenson
11.	Magnus Unemo
12.	Bea Vuylsteke
13.	Judith Wasserheit

STI External Review Group: Working group for chlamydia

	Name and address	Region	Sex
1.	Laith Abu-Raddad Biostatistics, Epidemiology and Biomathematics Research Core Infectious Disease Epidemiology Group Department of Public Health Weill Cornell Medical College Cornell University Qatar Foundation – Education City Qatar	EMR	M
2.	Adele Benaken-Schwartz Ministry of Health STI, AIDS and Viral Hepatitis Department SAF Sul Trecho 2, Ed. Premium Torre I, Térreo, Sala 12 70.070-600 – Brasília – DF Brazil	AMR	F
3.	Mircea Betiu Nicolae Testemițanu State University of Medicine and Pharmacy Republic of Moldova	EUR	M
4.	Anupong Chitwarakorn Department of Diseases Control Bureau of AIDS, TB and STIs Ministry of Public Health Nonthaburi Thailand	SEAR	M

5.	Anjana Das FHI 360 New Delhi India	SEAR	F
6.	Carolyn Deal National Institute of Allergy and Infectious Diseases (NIAID) United States Department of Health and Human Services National Institutes of Health Washington, DC USA	AMR	F
7.	Margaret Gale-Rowe Professional Guidelines and Public Health Practice Division Centre for Communicable Diseases and Infection Control Public Health Agency of Canada Ottawa, Ontario Canada	AMR	F
8.	William M. Geisler Medicine and Epidemiology University of Alabama at Birmingham Division of Infectious Diseases 703 19th Street South Zeigler Research Building, Room 242 Birmingham, AL 35294-0007 USA	AMR	M
9.	Amina El Kettani Direction de l'Epidémiologie Service des MST-sida Ministry of Health 71 Avenue Ibn Sinaa, Agdal Rabat Morocco	EMR	F
10.	Ahmed Latif Public Health Consultant Zimbabwe	AFR	M
11.	Mizan Kiros Disease Prevention and Control Directorate Federal Ministry of Health Ethiopia	AFR	M
12.	Philippe Mayaud Clinical Research Department Faculty of Infectious and Tropical Diseases London School of Hygiene and Tropical Medicine Keppel Street London WC1E 7HT United Kingdom	EUR	M

13.	David McCartney Research and Technical Support International Planned Parenthood Federation (IPPF) 4 Newhams Row, London SE1 3UZ United Kingdom	EUR	M
14.	Ali M. Mir Population Council No. 7 Street 62, Sector F/6-3 Islamabad Pakistan	SEAR	M
15.	Nuriye Ortayli United Nations Population Fund (UNFPA) 605 Third Avenue, 4rd floor New York, NY 10158 USA	AMR	F
16.	Khantanouvieng Sayabounthavong Ministry of Health Lao People's Democratic Republic	WPR	M
17.	Aman Kumar Singh Department of AIDS Control (National AIDS Control Organization) Ministry of Health and Family Welfare Government of India Chandralok Building, 9th Floor, 36, Janpath New Delhi 110001 India	SEAR	M

AFR: WHO African Region; AMR: WHO Region of the Americas; EMR: WHO Eastern Mediterranean Region;
EUR: WHO European Region; SEAR: WHO South-East Asia Region; WPR: WHO Western Pacific Region

ANNEX B: DETAILED METHODS FOR GUIDELINE DEVELOPMENT

QUESTIONS AND OUTCOMES

To determine which recommendations to update, in December 2013 the World Health Organization (WHO) Department of Reproductive Health and Research reviewed current recommendations of key international guidelines:

- Sexually transmitted diseases treatment guidelines, 2010, Department of Health and Human Services, United States Centers for Disease Control and Prevention (CDC)⁴;
- United Kingdom national guidelines for the management of sexually transmitted infections, British Association for Sexual Health and HIV (BASHH), 2006–2011;⁵
- Canadian guidelines on sexually transmitted infections, Public Health Agency of Canada, 2013–2014;⁶
- European sexually transmitted infections guidelines, International Union of Sexually Transmitted Infections (IUSTI);⁷
- National management guidelines for sexually transmissible infections, Sexual Health Society of Victoria, Australia, 2008;⁸
- National guideline for the management and control of sexually transmitted infections (STIs), National Department of Health, South Africa, 2009;⁹ and
- National guidelines on prevention, management and control of reproductive tract infections including sexually transmitted infections, Ministry of Health and Family Welfare, Government of India, August 2007.¹⁰

Based on the review, four proposed categories of sexually transmitted infection (STI) conditions were prioritized:

- a. STI conditions included in the 2003 WHO STI guidelines¹¹ that were selected by the GDG to be reviewed and updated in the new WHO STI guidelines. These are important and common conditions.
- b. STI conditions not included in the 2003 WHO STI guidelines that were selected by the GDG to be reviewed and added in the new WHO STI guidelines. These are important and common conditions.
- c. STI conditions included in the 2003 WHO STI guidelines that were not updated but were selected by the GDG to be included in the new WHO STI guidelines. These STI conditions are rare and diagnosis is not often made in the majority of settings, or it is unlikely that there is new information available as a basis for making any changes to the 2003 WHO STI recommendations.
- d. STI conditions not included in the 2003 WHO STI guidelines that are part of other national guidelines, but were not selected by the GDG to be included in the new WHO STI guidelines. These conditions are rare and difficult to diagnose in the majority of settings, or it is unlikely that new research or information has become available; there are existing recommendations for these conditions that can be applied in other settings (e.g. reference hospitals that manage complicated conditions).

A meeting was held in December 2013, at which the Guideline Development Group (GDG) discussed and decided on the initial list of population, intervention, comparator and outcome (PICO) questions identified by WHO. After the meeting, surveys pertaining to each of the four STI topic areas (i.e. gonorrhoea, chlamydia, syphilis and herpes simplex virus type 2 [HSV-2]) were administered among subgroups of the GDG members with expertise relating to the relevant STIs. The goal of the surveys was to rank the population, interventions and outcomes for each specific STI condition by importance. The surveys required the members of the STI subgroups to rank the population, interventions and outcomes on a scale of 1 to 9, from lowest to highest priority.

4 Available at: <http://www.cdc.gov/std/treatment/2010/std-treatment-2010-rr5912.pdf>

5 Available at: <http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx?hkey=072c83ed-0e9b-44b2-a989-7c84e4fbd9de>

6 Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php>

7 Available at: <http://www.iusti.org/regions/europe/euroguidelines.htm>

8 Melbourne Sexual Health Centre Treatment Guidelines, available at: <http://mshc.org.au/HealthProfessional/MSHCTreatmentGuidelines/tabid/116/Default>

9 Lewis DA, Maruma E. Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: what's new and why? *South Afr J Epidemiol Infect.* 2009;24(2):6-9 (<http://apps.who.int/medicinedocs/documents/s18369en/s18369en.pdf>, accessed 14 June 2016).

10 Available at: http://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_117313.pdf

11 Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2003 (<http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf>, accessed 30 May 2016).

Four different priority STI surveys were conducted, and each survey attained a 90–100% response rate from the STI subgroup members. The survey results for priority populations, interventions and outcomes were analysed. Populations, interventions and outcomes with an average rating of 7 to 9 were considered “critical”; those with an average rating of 4 to 6 were considered “important”; and those with an average rating of 1 to 3 were considered “not important” and were thus not covered in the guidelines. Some questions that scored less than 7 were kept for consistency.

The number of comparisons in each question was also reduced; only “critical” interventions were compared with each other and with important interventions. Thus, “important” interventions were not compared to each other.

A revised list of questions was then compiled and all members of the full STI GDG were requested to review the priority questions. The priority questions were then revised based on this feedback.

Six questions were identified for the update of the chlamydial infections guideline. Each question is framed using the PICO format (population, intervention, comparator and outcome). Each question corresponds to a recommendation.

PRIORITY QUESTIONS AND OUTCOMES FOR *CHLAMYDIA TRACHOMATIS*

1. Uncomplicated genital (cervix, urethra) chlamydial infections in adults and adolescents

Population	Intervention	Comparator	Outcome
Adults and adolescents with uncomplicated genital (cervix, urethra) chlamydial infections	Azithromycin 1 g orally x 1 dose Doxycycline 100 mg twice daily x 7 days	Doxycycline extended release (ER) 200 mg daily x 7 days Erythromycin 500 mg orally, four times daily x 7 days Erythromycin ethylsuccinate (ES) 800 mg orally, four times daily x 7 days Erythromycin 500 mg orally, twice daily x 10–14 days Amoxicillin 500 mg orally, thrice daily x 7 days Quinolones	Critical: Clinical cure, microbiological cure, STI complications, side-effects (including allergy, toxicity, gastro), compliance Important: Quality of life, HIV transmission and acquisition, partner transmission

2. Uncomplicated anorectal chlamydial infections in adults and adolescents, excluding lymphogranuloma venereum (LGV)

Population	Intervention	Comparator	Outcome
Adults and adolescents with uncomplicated anorectal chlamydial infections (excluding LGV)	Azithromycin 1 g orally x 1 dose Doxycycline 100 mg twice daily x 7 days	Doxycycline (ER) 200 mg daily x 7 days Erythromycin 500 mg orally, four times daily x 7 days Erythromycin ES 800 mg orally, four times daily x 7 days Erythromycin 500 mg orally, twice daily x 10–14 days Amoxicillin 500 mg orally, thrice daily x 7 days Quinolones	Critical: Clinical cure, microbiological cure, STI complications, side-effects (including allergy, toxicity, gastro), compliance Important: Quality of life, HIV transmission and acquisition, partner transmission

3a–c. Chlamydia in pregnancy

Population	Intervention	Comparator	Outcome
Pregnant women with chlamydia	Azithromycin 1 g orally x 1 dose Erythromycin 500 mg orally, four times daily x 7 days	Amoxicillin 500 mg orally, thrice daily x 7 days Erythromycin 500 mg orally, twice daily x 14 days Erythromycin 250 mg orally, four times daily x 14 days Erythromycin ES 800 mg orally, four times daily x 7 days Erythromycin ES 400 mg orally, four times daily x 14 days	Critical: Fetal outcomes (e.g. teratogenicity, toxicity), fetal loss, prematurity/low birth weight, chorioamnionitis, infant pneumonitis/neonatal ophthalmia, postpartum endometritis, microbiological cure, side-effects (including allergy, toxicity, gastro), clinical cure (symptoms), compliance Important: HIV acquisition, quality of life, transmission to partner

4. Lymphogranuloma venereum (LGV) in all populations

Population	Intervention	Comparator	Outcome
Adults and adolescents with LGV	Doxycycline 100 mg twice daily x 21 days Azithromycin 1 g orally once a week x 1–3 weeks	Doxycycline 100 mg twice daily x 14 days Erythromycin base 500 mg orally, four times daily x 21 days	Critical: Clinical cure, microbiological cure Important: STI complications, side-effects (including allergy, toxicity, gastro), quality of life, HIV transmission and acquisition, compliance, LGV transmission to partner

5. Ophthalmia neonatorum treatment

Population	Intervention and comparator	Outcome
Neonates with neonatal conjunctivitis	Erythromycin in 4 divided doses orally, daily x 14 days: 20 mg/kg/day, 30 mg/kg/day, or 50 mg/kg/day Azithromycin 20 mg/kg/day orally, daily x 3 days Trimethoprim 40 mg + sulfa 200 mg orally, twice daily x 14 days	Critical: Clinical cure, microbiological cure, Complications, side-effects (including allergy, toxicity, gastro), antimicrobial resistance, compliance

6 and 7. Ophthalmia neonatorum prophylaxis

Population	Intervention and comparator	Outcome
Neonates at risk for ophthalmia neonatorum	Ophthalmic ointment in each eye at the time of delivery: Erythromycin 0.5% Silver nitrate 1% Chloramphenicol Tetracycline 1% Povidone iodine 2.5%	Critical: Absence of conjunctivitis, keratitis, complications, blindness, corneal scarring, antimicrobial resistance

REVIEWS OF THE EVIDENCE

SEARCH FOR EVIDENCE FOR EFFECTS OF INTERVENTIONS

To avoid duplication of reviews that have been previously published, evidence was searched using a hierarchical approach. The team first searched for synthesized evidence then searched the primary studies for all the factors needed to complete the evidence-to-decision framework for each question (i.e. benefits and harms, patient values, acceptability, feasibility, equity and costs).

The hierarchical approach consisted of identifying pre-existing synthesized evidence, including from previously published guidelines that included systematic reviews of the literature. When synthesized evidence about benefits and harms for an intervention was not available or the synthesized evidence was not up to date, a new systematic review of randomized controlled trials (RCTs) and non-randomized studies was conducted.

The search strategies were developed by an information specialist trained in systematic reviews. The strategies included the use of keywords from the controlled vocabulary of the database and text words based on the PICO questions. There were no restrictions based on language, publication status or study design. RCTs were included for critical and important outcomes, and non-randomized studies for critical outcomes when no evidence was available from RCTs. Additional strategies included contacting Cochrane review groups and authors of study protocols.

The Cochrane Library suite of databases (Cochrane Database of Systematic Reviews [CDSR], Database of Abstracts of Reviews of Effects [DARE], Health Technology Assessment [HTA] database and the American College of Physicians [ACP] Journal Club) was searched for published systematic reviews and protocols from 2004 to 2015.

Search strategy:

1. chlamydia.mp.
2. trachomatis.mp.
3. ct infection*.tw.
4. or/1-3

Primary studies were searched for in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases. Search end dates for each PICO question varied between March and October 2015 (see list below). The strategies included searching for subject headings and text words that included chlamydia and specific interventions (e.g. medication names and classes). Additional strategies included checking reference lists and consulting with the GDG for any missed articles. We searched for RCTs for critical and important outcomes, and non-randomized studies for critical outcomes when no evidence was available from RCTs.

Search end dates:

- Uncomplicated genital (cervix, urethra) chlamydial infections in adults and adolescents: up to March 2015
- Uncomplicated anorectal chlamydial infections (excluding LGV) in adults and adolescents: up to June 2015
- Chlamydia in pregnancy: up to 1 June 2015; up to 1 December 2015 for non-randomized comparative studies
- Lymphogranuloma venereum in all populations: up to June 2015
- Ophthalmia neonatorum treatment: up to May 2015
- Ophthalmia neonatorum prevention: up to October 2015.

SCREENING STUDIES, DATA EXTRACTION AND ANALYSIS

Two researchers independently screened titles and abstracts of systematic reviews identified through database searching to determine studies eligible for inclusion in the analysis. Disagreements were resolved by discussing study inclusion with a third member of the research team. Data were extracted using a pilot-tested form for patient characteristics (including the subgroups identified by the GDG), diagnosis, treatment (dose, schedule, etc.), setting, follow-up and outcomes. Two investigators independently abstracted data. Risk of bias of each study was also assessed using risk of bias tools appropriate for RCTs (http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm) and using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I; previously called ACROBAT) tool to assess non-randomized studies (www.riskofbias.info).

To measure the treatment effect, the data were analysed using RevMan 5.2.¹²

For dichotomous outcomes, we calculated relative risks with 95% confidence intervals (e.g. risk ratios and odds ratios) by pooling results from RCTs and pooling results from non-randomized studies using the random effects model. Moderate to high heterogeneity ($I^2 > 50\%$) was explored. Effects were converted to absolute effects using the calculated relative effect and a representative baseline risk (agreed upon by the GDG). When non-randomized studies with one group were included, a pooled proportion of an event (and confidence intervals) were calculated across the studies using the generic inverse variance. For continuous outcomes, a mean difference or a standardized mean difference (when studies used different scales to measure an outcome) was calculated. When possible, the forest plots of the meta-analyses were made available to the GDG.

When data could not be pooled across studies, narrative synthesis methods were used (see <http://methods.cochrane.org/sites/methods.cochrane.org/files/Mckenzie.pdf>). Results were presented in tables (e.g. median effects with interquartile ranges), or were narratively described by direction of the effect or by statistical significance as reported in the primary study.

PATIENT VALUES AND PREFERENCES, ACCEPTABILITY, EQUITY AND FEASIBILITY

Studies on patient values and preferences, acceptability, equity and feasibility were searched for and screened using two methods. First, while screening studies for the effects of treatments and costs, two investigators identified studies of potential relevance in these areas. Secondly, a separate search was conducted in MEDLINE, Embase and PsycINFO from January 2000 to July 2015. Text words and keywords for the different STIs were used in combination with words such as "preference", "adherence", "satisfaction", "attitudes", "health utilities" and "value", "equity" and "feasibility". The results included 2563 unique references. Two investigators screened the studies, and 162 studies were identified for full text retrieval. Any study design was included that addressed equity or feasibility. In addition, when adherence was measured in RCTs or non-randomized studies, the data were collected, synthesized and presented in the evidence profiles for each PICO question.

The following study designs were included:

- a. Patient utilities and health status values studies: These studies examine how patients value alternative health states and their experiences with treatment. The measurement techniques used can include: standard gamble, time trade-off, visual analogue scale, or mapping results based on generic surveys (EuroQol five dimensions health questionnaire [EQ-5D] or the 36-Item Short Form Health Survey [SF-36]) or specific measurement (e.g. St George Respiratory Questionnaire) of health-related quality of life.
- b. Studies of patients' direct choices when presented with decision aids: These studies examine the choices patients make when presented with decision aids for management options (i.e. probabilistic trade-off techniques).
- c. Studies on non-utility measurement of health states: These studies quantitatively examine patients' views, attitudes, satisfaction or preferences through questionnaires or scales; these are neither utility studies nor studies of patients' responses to decision aids. Patients are asked about how desirable or aversive a particular outcome is for them. This category includes some studies that use questionnaires or scales.
- d. Qualitative studies: These studies explore patients' views, attitudes, satisfactions or preferences related to different treatment options based on qualitative research methods including focus group discussions, interviews, etc.

12 RevMan (Computer Program). Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration; 2012.

From the search, we included 17 studies reporting information relating to different STIs. In many instances, data for all infections informed the evidence for chlamydia specifically.

RESOURCES

We searched the published literature for evidence on use of resources and obtained data on direct costs of medicines.

Based on the list of possible treatments identified by the GDG, an estimate of the cost associated with each alternative was calculated. This costing estimate refers only to the actual market price of the medication and does not include the costs of other resources that could be involved, such as syringes, injection time or needle disposal.

Data were presented in a table and included: treatment, dose per day, treatment duration, days, medicine cost per dose, medicine cost per full course of treatment, and 25% of procurement costs (as defined in the 2014 MSH International drug price indicator guide)¹³. A final price for a full course of treatment for each medicine by dosage was calculated as the number of doses per day, multiplied by the number of days of the treatment, plus 25% of the procurement costs for the medicines used. The unit price of the medicine was obtained from the median prices provided in the 2014 MSH International drug price indicator guide and information available on the Internet. In order to determine a precise and reliable estimate, the price per unit (all expressed in US dollars) was provided only when the information available matched the dosage of interest (grams per pill or 1000 units per vial). No calculations were made based on assumptions about the cost per unit of hypothetical packaging not listed in the directory.

The major medical databases were also searched (MEDLINE, Embase and the Cochrane Library for Economic Evaluation and Technology Assessment reports) from January 2005 to July 2015. Three studies addressed the cost-effectiveness of different treatment strategies for chlamydia. In addition, while screening studies for the effects of treatments, two investigators also identified studies of potential relevance for costs, and abstracted data regarding possible resources to be considered during the decision-making process.

13 International drug price indicator guide, 2014 edition (updated annually). Medford (MA): Management Science for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).

APPLYING THE GRADE APPROACH TO MAKING THE RECOMMENDATIONS

EVIDENCE PROFILES

An evidence profile was made for each PICO question using the GRADEpro software (www.grade.pro.org). Each profile included the critical and important outcomes, the relative and absolute effects, and the quality of evidence according to the GRADE domains (see the GRADE handbook)¹⁴. Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose–response curve and other considerations that may affect the quality of the evidence. Two investigators used the GRADE approach to assess the quality and level of certainty of the evidence. The evidence profiles for each recommendation are available in Web annex D.

EVIDENCE-TO-DECISION FRAMEWORKS

Evidence-to-decision frameworks were also developed using GRADEpro software (www.grade.pro.org). Evidence-to-decision frameworks present the desirable and undesirable effects of the interventions, the value of the outcomes, the costs and resource use, the acceptability of the interventions to all stakeholders, the impact on health equity, and the feasibility of implementation (i.e. the GRADE criteria for making decisions). The evidence-to-decision frameworks are based on a population perspective for these recommendations. All GRADE criteria were considered from this perspective.

MAKING THE RECOMMENDATIONS

In October 2015, the GDG met to make the recommendations. This meeting was facilitated by two co-chairs – one with expertise in GRADE and the other with clinical expertise of chlamydia. During the meeting, the evidence profiles and evidence-to-decision frameworks were presented by the methodologists. The GDG discussed each GRADE criterion and judged which intervention was favoured. Then a final decision and guideline recommendation was developed. The goal was to arrive at agreement across all members of the GDG and this was facilitated by the chairpersons through discussion. When there was disagreement for a criterion, it was noted in the evidence-to-decision framework for the relevant judgement. If there was disagreement for any of the final recommendations, the plan was for the GDG to vote and the numbers to be recorded. Because there was no disagreement for any of the final recommendations, however, votes were not taken or reported in these guidelines.

The GDG made a strong or conditional recommendation for or against each intervention and described special circumstances in the remarks. Research implications were also developed and presented, based on the gaps identified in the evidence. Following the meeting, the recommendations were finalized via teleconference, and final approval was obtained from the GDG members electronically. All decisions and discussions from the GDG for each recommendation are available in the evidence-to-decision frameworks in Web annex D.

14 Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook. Hamilton, Ontario: McMaster University and Evidence Prime Inc.; 2013 (http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html, accessed 31 May 2016).

ANNEX C: LISTS OF REFERENCES FOR REVIEWED EVIDENCE

RECOMMENDATION 1

Treatments for adults and adolescents with uncomplicated genital (cervix, urethra) chlamydial infections

Systematic review

1. Páez-Canro C, Martínez-Martínez F, Alzate JP, Lethaby A, Gaitán HG. Antibiotics for treating genital *Chlamydia trachomatis* infection in men and non-pregnant women (protocol). *Cochrane Database Syst Rev*. 2013;(12):CD010871.

Included studies

1. Bowie WR, Yu JS, Fawcett A, Jones HD. Tetracycline in nongonococcal urethritis. Comparison of 2 g and 1 g daily for seven days. *Br J Vener Dis*. 1980;56(5):332-6.
2. Campbell WF, Dodson MG. Clindamycin therapy for *Chlamydia trachomatis* in women. *Am J Obstet Gynecol*. 1990;162(2):343-7.
3. Cramers M, Kaspersen P, From E, Møller BR. Pivampicillin compared with erythromycin for treating women with genital *Chlamydia trachomatis* infection. *Genitourin Med*. 1988;64(4):247-8.
4. Csángó PA, Gundersen T, Anestad G. Doxycycline in the treatment of chlamydial urethritis: a therapeutic study. *Pharmatherapeutica*. 1980;2(5):341-5.
5. Fong IW, Linton W, Simbul M, Thorup R, McLaughlin B, Rahm V, et al. Treatment of nongonococcal urethritis with ciprofloxacin. *Am J Med*. 1987;82(4A):311-6.
6. Geisler WM, Koltun WD, Abdelsayed N, Burigo J, Mena L, Taylor SN, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital *Chlamydia trachomatis* infection: a randomized, double-blind, double-dummy active-controlled, multicenter trial. *Clin Infect Dis*. 2012;55(1):82-8. doi:10.1093/cid/cis291.
7. Guven MA, Gunyeli I, Dogan M, Ciragil P, Bakaris S, Gul M. The demographic and behavioural profile of women with cervicitis infected with *Chlamydia trachomatis*, *Mycoplasma hominis* and *Ureaplasma urealyticum* and the comparison of two medical regimens. *Arch Gynecol Obstet*. 2005;272:197-200.
8. Hammerschlag MR, Golden NH, Oh MK, Gelling M, Sturdevant M, Brown PR, et al. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. *J Pediatr*. 1993;122(6):961-5.
9. Hawkins DA, Taylor-Robinson D, Evans RT, Furr PM, Harris JR. Unsuccessful treatment of non-gonococcal urethritis with rosoxacin provides information on the aetiology of the disease. *Genitourin Med*. 1985;61(1):51-5.
10. Hooton TM, Rogers ME, Medina TG, Kuwamura LE, Ewers C, Roberts PL, et al. Ciprofloxacin compared with doxycycline for nongonococcal urethritis. Ineffectiveness against *Chlamydia trachomatis* due to relapsing infection. *JAMA*. 1990;264(11):1418-21.
11. Ibsen HH, Møller BR, Halkier-Sørensen L, From E. Treatment of nongonococcal urethritis: comparison of ofloxacin and erythromycin. *Sex Transm Dis*. 1989;16(1):32-5.
12. Kitchen VS, Donegan C, Ward H, Thomas B, Harris JR, Taylor-Robinson D. Comparison of ofloxacin with doxycycline in the treatment of non-gonococcal urethritis and cervical chlamydial infection. *J Antimicrob Chemother*. 1990;26(Suppl D):99-105.
13. Lauharanta J, Saarinen K, Mustonen MT, Happonen HP. Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males. *J Antimicrob Chemother*. 1993;31(Suppl E):177-83.
14. Lister PJ, Balechandran T, Ridgway GL, Robinson AJ. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. *J Antimicrob Chemother*. 1993;31(Suppl E):185-92.
15. Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. *Clin Infect Dis*. 2013;56(7):934-42.
16. Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. *N Engl J Med*. 1992;327(13):921-5.
17. McCormack WM, Dalu ZA, Martin DH, Hook EW 3rd, Laisi R, Kell P, et al.; Trovafloxacin Chlamydial Urethritis/Cervicitis Study Group. Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated Chlamydial urethritis and cervicitis. *Sex Transm Dis*. 1999;26(9):531-6.
18. McCormack WM, Martin DH, Hook EW 3rd, Jones RB. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of *Chlamydia trachomatis* endocervical infection. *Infect Dis Obstet and Gynecol*. 1998;6(3):109-15.
19. Nilsen A, Halsos A, Johansen A, Hansen E, Tørud E, Moseng D, et al. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males. *Genitourin Med*. 1992;68(5):325-7.
20. Pereira CA, Montagnini SD. A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of nongonococcal urethritis caused by *Chlamydia trachomatis*. *Arquivos brasileiros de medicina*. 1994;68(1):51-3.
21. Robson HG, Shah PP, Lalonde RG, Hayes L, Senikas VM. Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with *Chlamydia trachomatis*. *Sex Trans Dis*. 1983;10(3):130-4.
22. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW 3rd, Cooper RH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. *JAMA*. 1995;274(7):545-9.
23. Thammar IV, Simmons PD, Thin RN, Darougar S, Yearsley P. Double-blind comparison of two regimens in the treatment of nongonococcal urethritis. Seven-day vs 21-day course of triple tetracycline (Deteclo). *Br J Vener Dis*. 1979;55(4):284-8.

24. Topic A, Skerk V, Puntaric A, Milavec Puretic V, Beus A, Begovac J. Azithromycin: 1.0 or 3.0 gram dose in the treatment of patients with asymptomatic urogenital chlamydial infections. *J Chemother*. 2006;18(1):115-6.
25. van der Willigen AH, Polak-Vogelzang AA, Habbema L, Wagenvoort JH. Clinical efficacy of ciprofloxacin versus doxycycline in the treatment of non-gonococcal urethritis in males. *Eur J Clin Microbiol Infect Dis*. 1988;7(5):658-61.

Patient values and preferences, acceptability and cost: specific to chlamydial infections

1. Dixon-Woods M, Stokes T, Young B, Phelps K, Windridge K, Shukla R. Choosing and using services for sexual health: a qualitative study of women's views. *Sex Transm Infect*. 2001;77(5):335-9.
2. International drug price indicator guide, 2014 edition (updated annually). Medford (MA): Management Sciences for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).
3. Sahin-Hodoglugil NN, Woods R, Pettifor A, Walsh J. A comparison of cost-effectiveness of three protocols for diagnosis and treatment of gonococcal and chlamydial infections in women in Africa. *Sex Transm Dis*. 2003;30:455-69.

Patient values and preferences, acceptability and cost: other sexually transmitted infections and conditions

1. Kingston M, Carlin E. Treatment of sexually transmitted infections with single-dose therapy: a double-edged sword. *Drugs*. 2002;62(6):871-8.
2. Nagarkar A, Mhaskar P. A systematic review on the prevalence and utilization of health care services for reproductive tract infections/sexually transmitted infections: evidence from India. *Indian J Sex Transm Dis*. 2015;36(1):18-25. doi:10.4103/0253-7184.156690.
3. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev*. 2014;4:CD007768.

Additional references

1. Amin A, Garcia Moreno C. Addressing gender-based violence to reduce risk of STI and HIV. *Sex Transm Infect*. 2013;89 (Suppl 1):A8. doi:10.1136/sextrans-2013-051184.0022.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;386(9995):743-800. doi:10.1016/S0140-6736(15)60692-4.
3. Holmes K. Sexually transmitted diseases, 4th edition. New York (NY): McGraw Hill; 2008.
4. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One*. 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304.

RECOMMENDATION 2

Treatments in adults and adolescents with uncomplicated anorectal chlamydial infections (excluding lymphogranuloma venereum)

Systematic review

1. Kong FY, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2015;70(5):1290-7. doi:10.1093/jac/dku574.

Included studies

1. Ding A, Challenor R. Rectal chlamydia in heterosexual women: more questions than answers. *Int J STD AIDS*. 2014. 25(8):587-92. doi:10.1177/0956462413515637.
2. Drummond F, Ryder N, Wand H, Guy R, Read P, McNulty AM, et al. Is azithromycin adequate treatment for asymptomatic rectal chlamydia? *Int J STD AIDS*. 2011;22(8):478-80. doi:10.1258/ijisa.2011.010490.
3. Elgalib A, Alexander S, Tong CY, White JA. Seven days of doxycycline is an effective treatment for asymptomatic rectal *Chlamydia trachomatis* infection. *Int J STD AIDS*. 2011;22(8):474-7. doi:10.1258/ijisa.2011.011134.
4. Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal *Chlamydia trachomatis* in men and women? *Sex Trans Infect*. 2012;88(5):352-4. doi:10.1136/sextrans-2011-050466.
5. Khosropour CM, Dombrowski JC, Barbee LA, Manhart LE, Golden MR. Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study. *Sex Transm Dis*. 2014;41(2):79-85. doi:10.1097/OLQ.0000000000000088.
6. Khosropour CM, Duan R, Metsch LR, Feaster DJ, Golden MR. Persistent/recurrent chlamydial infection among STD clinic patients treated with CDC-recommended therapies. Abstracts of the STI and AIDS World Congress, Vienna, Austria. *Sex Transm Infect*. 2013;89(Suppl 1):A29. doi:10.1136/sextrans-2013-051184.0092.
7. Steedman NM, McMillan A. Treatment of asymptomatic rectal *Chlamydia trachomatis*: is single-dose azithromycin effective? *Int J STD AIDS*. 2009;20(1):16-8. doi:10.1258/ijisa.2008.008211.
8. White JA. Manifestations and management of lymphogranuloma venereum. *Curr Opin Infect Dis*. 2009;22(1):57-66. doi:10.1097/QCO.0b013e328320a8ae.

Patient values and preferences, acceptability and cost: specific to chlamydial infections

1. Dixon-Woods M, Stokes T, Young B, Phelps K, Windridge K, Shukla R. Choosing and using services for sexual health: a qualitative study of women's views. *Sex Transm Infect*. 2001;77(5):335-9.
2. International drug price indicator guide, 2014 edition (updated annually). Medford (MA): Management Sciences for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).

Patient values and preferences, acceptability and cost: other sexually transmitted infections and conditions

1. Nagarkar A, Mhaskar P. A systematic review on the prevalence and utilization of health care services for reproductive tract infections/sexually transmitted infections: evidence from India. *Indian J Sex Transm Dis.* 2015;36(1):18-25. doi:10.4103/0253-7184.156690.
2. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014;4:CD007768.

Additional references

1. Amin A, Garcia Moreno C. Addressing gender-based violence to reduce risk of STI and HIV. *Sex Transm Infect.* 2013;89(Suppl 1):A8.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386(9995):743–800. doi:10.1016/S0140-6736(15)60692-4.
3. Holmes K. Sexually transmitted diseases, 4th edition. New York (NY): McGraw Hill; 2008.
4. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One.* 2015;10(12):e0143304. doi:10.1371/journal.pone.0143304.

RECOMMENDATIONS 3A, 3B, 3C

Treatments in pregnant women with chlamydial infections

Systematic review

1. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database Syst Rev.* 2013;(1):CD000262.

Included studies

1. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. *Obstet Gynecol.* 1998;91(2):165–8.
2. Alary M, Joly JR, Moutquin JM, Mondor M, Boucher M, Fortier A, et al. Randomised comparison of amoxicillin and erythromycin in treatment of genital chlamydial infection in pregnancy. *Lancet.* 1994;344(8935):1461–5.
3. Alger LS, Lovchik JC. Comparative efficacy of clindamycin versus erythromycin in eradication of antenatal *Chlamydia trachomatis*. *Am J Obstet Gynecol.* 1991;165(2):375–81.
4. Bell TA, Sandstrom IK, Eschenbach DA, Hummel D, Kuo C, Wang S, et al. Treatment of *Chlamydia trachomatis* in pregnancy with amoxicillin. In: Marsh PA editor(s). *Chlamydial infections.* Elsevier Biomedical Press; 1982:221–4.

5. Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. *Obstet Gynecol.* 1994;84(1):61–3.
6. Crombleholme WR, Schachter J, Grossman M, Landers DV, Sweet RL. Amoxicillin therapy for *Chlamydia trachomatis* in pregnancy. *Obstet Gynecol.* 1990;75(5):752–6.
7. Edwards MS, Newman RB, Carter SG, Leboeuf FW, Menard MK, Rainwater KP. Randomized clinical trial of azithromycin for the treatment of Chlamydia cervicitis in pregnancy. *Infect Dis Obstet Gynecol.* 1996;4(6):333–7.
8. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of *Chlamydia trachomatis* in pregnancy. *Am J Obstet Gynecol.* 2001;184(7):1352–4
9. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of *Chlamydia trachomatis* in pregnancy. *Infect Dis Obstet Gynecol.* 2001;9(4):197–202.
10. Magat AH, Alger LS, Nagey DA, Hatch V, Lovchik JC. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of *Chlamydia trachomatis* in pregnancy. *Obstet Gynecol.* 1993;81(5 Pt 1):745–9.
11. Martin DH, Eschenbach DA, Cotch MF, Nugent RP, Rao AV, Klebanoff MA, et al. Double-blind placebo-controlled treatment trial of *Chlamydia trachomatis* endocervical infections in pregnant women. *Infect Dis Obstet Gynecol.* 1997;5(1):10–7.
12. Nadafi M, Abdali KH, Parsanejad ME, Rajaei-Fard AR, Kaviani M. A comparison of amoxicillin and erythromycin for asymptomatic *Chlamydia trachomatis* infection in pregnancy. *Int J Gynaecol Obstet.* 2005;90(2):142–3.
13. Rahangdale L, Guerry S, Bauer HM, Packer L, Rhew M, Baxter R, et al. An observational cohort study of *Chlamydia trachomatis* treatment in pregnancy. *Sex Transm Dis.* 2006;33(2):106–10.
14. Rosenn M, Macones GA, Silverman N. A randomized trial of erythromycin and azithromycin for the treatment of chlamydia infection in pregnancy. *Am J Obstet Gynecol.* 1996;174:410.
15. Rosenn MF, Macones GA, Silverman NS. Randomized trial of erythromycin and azithromycin for treatment of chlamydial infection in pregnancy. *Infect Dis Obstet Gynecol.* 1995;3(6):241–4.
16. Silverman NS, Hochman M, Sullivan M, Womack M. A randomized prospective trial of amoxicillin versus erythromycin for the treatment of chlamydia in pregnancy. *Am J Obstet Gynecol.* 1993;168:420.
17. Silverman NS, Sullivan M, Hochman M, Womack M, Jungkind DL. A randomized, prospective trial comparing amoxicillin and erythromycin for the treatment of *Chlamydia trachomatis* in pregnancy. *Am J Obstet Gynecol.* 1994;170(3):829–32.
18. Turrentine MA, Troyer L, Gonik B. Randomized prospective study comparing erythromycin, amoxicillin and clindamycin for the treatment of *Chlamydia trachomatis* in pregnancy. *Infect Dis Obstet Gynecol.* 1995;2(5):205–9.
19. Wehbeh HA, Ruggierio RM, Shahem S, Lopez G, Ali Y. Single-dose azithromycin for chlamydia in pregnant women. *J Reprod Med.* 1998 Jun;43(6):509–14.

Reviews and studies for adverse outcomes

1. Morency AM, Bujold E. The effect of second-trimester antibiotic therapy on the rate of preterm birth. *J Obstet Gynaecol Can.* 2007;29(1):35-44.
2. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. *Br J Clin Pharmacol.* 2012;74(6):1053-62. doi:10.1111/j.1365-2125.2012.04286.x.
3. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, Neilson JP. The APLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. *PLoS Med.* 2009;6(12):e1000191. doi:10.1371/journal.pmed.1000191.

Patient values and preferences, acceptability and cost: specific to chlamydial infections

1. Dixon-Woods M, Stokes T, Young B, Phelps K, Windridge K, Shukla R. Choosing and using services for sexual health: a qualitative study of women's views. *Sex Transm Infect.* 2001;77(5):335-9.
2. International drug price indicator guide, 2014 edition (undated annually). Medford (MA): Management Science for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).
3. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for *Chlamydia trachomatis* infection during pregnancy: a meta-analysis of randomised controlled trials. *Int J Antimicrob Agents.* 2007;30(3):213-21.

Patient values and preferences, acceptability and cost: other sexually transmitted infections and conditions

1. Nagarkar A, Mhaskar P. A systematic review on the prevalence and utilization of health care services for reproductive tract infections/sexually transmitted infections: evidence from India. *Indian J Sex Transm Dis.* 2015;36(1):18-25. doi:10.4103/0253-7184.156690.
2. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014;4:CD007768.

Additional references

1. Amin A, Garcia Moreno C. Addressing gender-based violence to reduce risk of STI and HIV. *Sex Transm Infect.* 2013;89(Suppl 1):A8.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386(9995):743-800. doi:10.1016/S0140-6736(15)60692-4.

RECOMMENDATION 4**Treatments for adults and adolescents with lymphogranuloma venereum****Included studies**

1. Ballard RC, Ye H, Matta A, Dangor Y, Radebe F. Treatment of chancroid with azithromycin. *Int J STD AIDS.* 1996;7(Suppl.1):9-12.
2. Collado CAM, Aguilar REB. Lymphogranuloma venereum. Clinical aspects, diagnostic methods and treatment of 120 patients. *Dermatologia Revista Mexicana.* 2003;47(1):5-12.
3. De Vries C, Smelov V, Middelburg JG, Pleijster J, Speksnijder AG, Morré SA. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. *Clin Infect Dis.* 2009;48(5):e53-e56. doi:10.1086/597011.
4. Heras E, Llibre JM, Martró E, Casabona J, Martin R, Sirera G. [Lymphogranuloma venereum proctocolitis in men with HIV-1 infection] *Enferm Infecc Microbiol Clin.* 2011;29(2):124-6 (in Spanish). doi:10.1016/j.eimc.2010.07.011. [correction in *Enferm Infecc Microbiol Clin.* 2012 Jun;30(6):357].
5. Hevia H, Honeyman J, De la Parra M. [Treatment of early syphilis and venereal lymphogranulomatosis with doxycycline]. *Rev Med Chil.* 1971;99(6):402-5 (in Spanish).
6. Hill SC, Hodson L, Smith A. An audit on the management of lymphogranuloma venereum in a sexual health clinic in London, UK. *Int J STD AIDS.* 2010;21(11):772-6. doi:10.1258/ijsa.2010.010329.
7. Kamarashev J, Riess CE, Mosimann J, Läubli S. Lymphogranuloma venereum in Zurich, Switzerland: *Chlamydia trachomatis* serovar L2 proctitis among men who have sex with men. *Swiss Med Wkly.* 2010;140(13-14):209-12. doi:smw-12962.
8. Krishnamurthy VR, Johnson M, Rangasamy J, Murali RVK. Efficacy of streptomycin, chloramphenicol, co-trimoxazole and doxycycline in lymphogranuloma venereum. *Indian J Sex Transm Dis.* 1982;3(1):26-8.
9. Marangoni A, D'Antuono A, Filippini A, Bellavista S, Baraldi C, Foschi C, et al. Lymphogranuloma venereum cases identified in patients attending a STD outpatients clinic in Italy. Poster (P2.013) presented 16 July 2013 at the STI & AIDS World Congress 2013, 14-17 July, Vienna, Austria.
10. Oud EV, de Vrieze NH, de Meij A, de Vries HJ. Pitfalls in the diagnosis and management of inguinal lymphogranuloma venereum: important lessons from a case series. *Sex Transm Infect.* 2014;90(4):279-82. doi:10.1136/sextrans-2013-051427.
11. Rodríguez-Domínguez M, Puerta T, Menéndez B, González-Alba JM, Rodríguez C, Hellin T, et al. Clinical and epidemiological characterization of a lymphogranuloma venereum outbreak in Madrid, Spain: co-circulation of two variants. *Clin Microbiol Infect.* 2014;20(3), 219-25. doi:10.1111/1469-0691.12256.
12. Sethi G, Allason-Jones E, Richens J, Annan NT, Hawkins D, Ekbote A, et al. Lymphogranuloma venereum presenting as genital ulceration and inguinal syndrome in men who have sex with men in London, UK. *Sex Transm Infect.* 2009;85(3):165-70. doi:10.1136/sti.2008.034348.
13. Vas A, Leighton J, Saxon C, Lebari D, Stott C, Ahmad S, et al. Audit of the clinical management of lymphogranuloma venereum in three inner-city genitourinary medicine clinics. *International Journal of STD and AIDS, Conference, 11th Spring Meeting of the British Association for Sexual Health and HIV (BASHH), 15-17 May 2013. Bristol, United Kingdom. Conference Publication.*

Patient values and preferences, acceptability and cost: specific to chlamydial infections

1. International drug price indicator guide, 2014 edition (updated annually). Medford (MA): Management Sciences for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).
2. Sahin-Hodoglugil NN, Woods R, Pettifor A, Walsh J. A comparison of cost-effectiveness of three protocols for diagnosis and treatment of gonococcal and chlamydial infections in women in Africa. *Sex Transm Dis.* 2003;30:455-69.

Patient values and preferences, acceptability and cost

1. Nagarkar A, Mhaskar P. A systematic review on the prevalence and utilization of health care services for reproductive tract infections/sexually transmitted infections: evidence from India. *Indian J Sex Transm Dis.* 2015;36(1):18-25. doi:10.4103/0253-7184.156690.
2. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014;4:CD007768.

Additional references

1. O'Farrell N, Morison L, Moodley P, Pillay K, Vanmali T, Quigley M, Sturm AW. Genital ulcers and concomitant complaints in men attending a sexually transmitted infections clinic: implications for sexually transmitted infections management. *Sex Transm Dis.* 2008;35:545-9. doi:10.1097/OLQ.0b013e31816a4f2e.

RECOMMENDATION 5**Treatment of chlamydial ophthalmia neonatorum****Included studies**

1. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. *Arch Pediatr Adolesc Med.* 2002;156(7):647-50.
2. Franssen L, Nsanze H, D'Costa L. Oral erythromycin estolate in nongonococcal neonatal conjunctivitis. *Eur J Sex Transm Dis.* 1986;3(2):85-9.
3. Heggie AD, Jaffe AC, Stuart LA, Thombre PS, Sorensen RU. Topical sulfacetamide vs oral erythromycin for neonatal chlamydial conjunctivitis. *Am J Dis Child.* 1985;139(6):564-6.
4. Hammerschlag MR, Chandler JW, Alexander ER, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. *Pediatr Infect Dis.* 1982;1(6):395-401.
5. Hammerschlag MR, Gelling M., Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. *Pediatr Infect Dis J.* 1998;17(11):1049-50.
6. Patamasucon PR, Retting PJ, Faust KL, Kusmiesz HT, Nelson JD. Oral v topical erythromycin therapies for chlamydial conjunctivitis. *Am J Dis Child.* 1982;136(9):817-21.
7. Rosenman MB, Mahon BE, Downs SM, Kleiman MB. Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to *Chlamydia trachomatis*. *Arch Pediatr Adolesc Med.* 2003;157(6):565-71.

8. Sandström I. Treatment of neonatal conjunctivitis. *Arch Ophthalmol.* 1987;105(7):925-8.
9. Sandström I, Kallings I, Melen B. Neonatal chlamydial conjunctivitis. A long term follow-up study. *Acta Paediatr Scand.* 1988;77(2):207-13.
10. Stenberg K, Mårdh PA. Chlamydial conjunctivitis in neonates and adults. History, clinical findings and follow-up. *Acta Ophthalmol.* 1990;68(6):651-7.
11. Stenberg K, Mårdh P. A. Treatment of chlamydial conjunctivitis in newborns and adults with erythromycin and roxithromycin. *J Antimicrob Chemother.* 1991;28(2):301-7.

Patient values and preferences, acceptability and cost: specific to chlamydial infections

1. Deogan CL, Bocangel MK, Wamala SP, Månsdotter AM. A cost-effectiveness analysis of the Chlamydia Monday – a community-based intervention to decrease the prevalence of chlamydia in Sweden. *Scand J Public Health.* 2010;38(2):141-50.
2. International Drug Price Indicator Guide, 2014 Edition (updated annually). Medford (MA): Management Sciences for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).

Additional references

1. Darling EK, McDonald H. A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. *J Midwifery Womens Health.* 2010;55(4):319-27. doi:10.1016/j.jmwh.2009.09.003.
2. Kakar S, Bhalla P, Maria A, Rana M, Chawla R, Mathur NB. *Chlamydia trachomatis* causing neonatal conjunctivitis in a tertiary care center. *Indian J Med Microbiol.* 2010;28(1):45-7. doi:10.4103/0255-0857.58728.

RECOMMENDATIONS 6 AND 7**Prevention of gonococcal and chlamydial ophthalmia neonatorum****Systematic reviews**

1. Darling EK, McDonald H. A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. *J Midwifery Womens Health.* 2010;55(4):319-27. doi:10.1016/j.jmwh.2009.09.003.
2. Kapoor VS, Whyte R, LaRoche RR. Interventions for preventing ophthalmia neonatorum (intervention protocol). *Cochrane Database Syst Rev.* 2015;(12):CD001862.
3. Mabry-Hernandez IR, Koenig HC. Ocular prophylaxis for gonococcal ophthalmia neonatorum: evidence update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. AHRQ Publication No. 10-05146. Rockville (MD): Agency for Healthcare Research and Quality; 2010.
4. Zuppa AA, D'Andrea V, Catenazzi P, Scorrano A, Romagnoli C. Ophthalmia neonatorum: what kind of prophylaxis? *J Matern Fetal Neonatal Med.* 2011;24(6):769-73. doi:10.3109/14767058.2010.531326.

Included studies

1. Ali Z, Khadije D, Elahe A, Mohammad M, Fateme Z, Narges Z. Prophylaxis of ophthalmia neonatorum comparison of betadine, erythromycin and no prophylaxis. *J Trop Pediatr*. 2007;53(6):388-92.
5. Brussieux J, Boisivon A, Théron HP, Faidherbe C, Machado N, Michelon B. [Prevention of neonatal conjunctivitis. A comparative clinical and bacteriologic study of 2 eyedrops: silver nitrate and oxytetracycline]. *Ann Pediatr*. 1991;36(9):637-41 (in French).
6. Chen JY. Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. *Pediatr Infect Dis J*. 1992;11(12):1026-30.
7. David M, Rumelt S, Weintraub Z. Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. *Ophthalmology*. 2011;118(7):1454-8.
8. Fischer PR, Reta BB. Prevention of neonatal conjunctivitis in Zaire. *Ann Trop Paediatr*. 1988;8(2):85-6.
9. Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. *N Engl J Med*. 1989;320(12):769-72.
10. Hammerschlag MR, Chandler JW, Alexander ER, English M, Chiang WT, Koutsky L, et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. *JAMA*. 1980;244(20):2291-3.
11. Hammerschlag MR, Chandler JW, Alexander ER, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. *Pediatr Infect Dis*. 1982;1(6):395-401.
12. Isenberg SJ, Apt L, Del Signore M, Gichuhi S, Berman NG. A double application approach to ophthalmia neonatorum prophylaxis. *Br J Ophthalmol*. 2003; 87(12):1449-52.
13. Isenberg SJ, Apt L, Wood M. A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. *N Engl J Med*. 1995;332(9):562-6.
14. Laga M, Plummer FA, Plot P, Datta P, Namaara W, Neinya-Achola JO, et al. Prophylaxis of gonococcal and chlamydial ophthalmia neonatorum. A comparison of silver nitrate and tetracycline. *N Engl J Med*. 1988;318(11):653-7.
15. Matinzadeh ZK, Beiragdar F, Kavemanesh Z, Abolgasemi H, Amirsalari S. Efficacy of topical ophthalmic prophylaxis in prevention of ophthalmia neonatorum. *Trop Doct*. 2007;37(1):47-9.
16. Ozkan H, Abacioglu H, Duman N, Celikkol B, Ozkutuk A. A controlled trial of efficacy and safety of povidone-iodine as prophylaxis against ophthalmia neonatorum. *Çocuk Sağlığı ve Hastalıkları Dergisi [J of Child Health Dis]*. 1999;42(4):459-67 (in Turkish).
17. Ramirez-Ortiz MA, Rodriguez-Almaraz M, Ochoa-Díazlopez H, Diaz-Prieto P, Rodriguez-Suárez RS. Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. *Br J Ophthalmology*. 2007;91(11):1430-4.
18. Steigleder GK. [Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis]. *Z Hautkr*. 1989;64(5):347 (in German).
19. Zaroni D, Isenberg SJ, Apt L. A comparison of silver nitrate with erythromycin for prophylaxis against ophthalmia neonatorum. *Clin Pediatr*. 1992;31(5):295-8.

Resistance data

1. Hedberg K, Ristinen TL, Soler JT, White KE, Hedberg CW, Osterholm MT, MacDonald KL. Outbreak of erythromycin resistant staphylococcal conjunctivitis in a newborn nursery. *Pediatr Infect Dis J*. 1990;9:268-73.
2. Isenberg SJ, Apt L, Wood M. A controlled trial of povidone iodine as prophylaxis against ophthalmia neonatorum. *N Engl J Med*. 1995;332:562-6.
3. Ison CA, Terry P, Bendayna K, Gill MJ, Adams J, Woodford N. Tetracycline-resistant gonococci in UK. *Lancet*. 1988;1:651-2.
4. Knapp JS, Zenilman JM, Biddle JW, Perkins GH, DeWitt WE, Thomas ML, et al. Frequency and distribution in the United States of strains of *Neisseria gonorrhoeae* with plasmid-mediated, high-level resistance to tetracycline. *J Infect Dis*. 1987;155:819-22.
5. Schwarcz SK, Zenilman JM, Schnell D, Knapp JS, Hook EW 3rd, Thompson S, et al. National surveillance of antimicrobial resistance in *Neisseria gonorrhoeae*. The Gonococcal Isolate Surveillance Project. *JAMA*. 1990;264:1413-7.

References related to patient values and preferences, acceptability and cost

1. Deogan CL, Bocangel MK, Wamala SP, Månsdotter AM. A cost-effectiveness analysis of the Chlamydia Monday – a community-based intervention to decrease the prevalence of chlamydia in Sweden. *Scand J Public Health*. 2010;38(2):141-50.
2. Keenan JD, Eckert S, Rutar T. Cost analysis of povidone-iodine for ophthalmia neonatorum prophylaxis. *Arch Ophthalmol*. 2010;128(1):136-7.
3. International Drug Price Indicator Guide, 2014 Edition (updated annually). Medford (MA): Management Sciences for Health; 2015 (http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2014.pdf, accessed 3 June 2016).

Additional references

1. Darling EK, McDonald H. A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. *J Midwifery Womens Health*. 2010;55(4):319-27. doi:10.1016/j.jmwh.2009.09.003.
2. Kakar S, Bhalla P, Maria A, Rana M, Chawla R, Mathur NB. *Chlamydia trachomatis* causing neonatal conjunctivitis in a tertiary care center. *Indian J Med Microbiol*. 2010;28(1):45-7. doi:10.4103/0255-0857.58728.

For more information, contact:

**Department of Reproductive
Health and Research**

World Health Organization
Avenue Appia 20, CH-1211 Geneva 27
Switzerland

Fax +41 22 791 4171

E-mail: reproductivehealth@who.int
www.who.int/reproductivehealth

